

FORM PCT/1999
(REV 5-93)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

Mewburn

U.S. APPLICATION NO. 09/463098
not yet assignedINTERNATIONAL APPLICATION NO.
PCT/EP99/03344INTERNATIONAL FILING DATE
14 May 1999PRIORITY DATE CLAIMED
19 May 1998

TITLE OF INVENTION

MIMOTOPE(S) OF HYPERVARIABLE REGION 1 OF THE E2 GLYCOPROTEIN OF HCV AND USES THEREOF

APPLICANT(S) FOR DO/EO/US

Alfredo NICOSIA; Armin LAHM; Anna TRAMONTANO; Riccardo CORTESE

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
 2. ☐ This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
 3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
 4. ☐ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
 5. ☐ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US)
 6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
 7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
 8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
 9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
 10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).
- Items 11. to 16. below concern other document(s) or information included:
11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
 12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
 13. ☒ A FIRST preliminary amendment.
☐ A SECOND or SUBSEQUENT preliminary amendment.
 14. ☐ A substitute specification.
 15. ☐ A change of power of attorney and/or address letter.
 16. ☒ Other items or information:
Copy of Form PCT/IB/308

09/463098

430 Rec'd PCT/PTO 18 JAN 2000

3 APPLICATION NO. (USPTO Form 37 CFR 1.53) not yet assigned		INTERNATIONAL APPLICATION NO. PCT/EP99/03344		ATTORNEY'S DOCKET NUMBER Newburn	
--	--	---	--	-------------------------------------	--

17. ☒ The following fees are submitted:

Basic National Fee (37 CFR 1.492(a)(1)-(5)):
Search Report has been prepared by the EPO or JPO..... 840.00

International preliminary examination fee paid to USPTO (37 CFR 1.482).....

No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2))..

Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....

International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4).....

ENTER APPROPRIATE BASIC FEE AMOUNT = \$ 840.00

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492(e)). \$ 130.00

Claims	Number Filed	Number Extra	Rate
Total claims	87	-28 -	67
Independent Claims	2	-3 -	0

Multiple dependent claims(s) (if applicable) + \$

TOTAL OF ABOVE CALCULATIONS = \$ 2,176.00

Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28). \$

SUBTOTAL = \$ 2,176.00

Processing fee of \$130.00 for furnishing the English translation later the ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492(f)). + \$ 0

TOTAL NATIONAL FEE = \$ 2,176.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property + \$ 0

TOTAL FEES ENCLOSED = \$ 2,176.00

Amount to be: refunded \$ charged \$

a. ☒ A check in the amount of \$ 2,176.00 to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 04-1406. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Kathleen D. Rigaut, Ph.D., J.D.
DANN, DORFMAN, HERRELL AND SKILLMAN
1601 Market Street, Suite 720
Philadelphia, Pennsylvania 19103

Kathleen D. Rigaut
SIGNATURE

Kathleen D. Rigaut, Ph.D., J.D.
NAME

43,047

REGISTRATION NUMBER

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of)
)
 Alfredo Nicosia et al.)
)
 Serial No. Not yet assigned)
 [Int. Appl. No. PCT/EP99/03344])
)
 Filed: May 14, 1999)
)
 For: "Mimotopes of Hyper-)
 Variable Region 1 of the)
 E2 Glycoprotein of HCV)
 and Uses Thereof)

PRELIMINARY AMENDMENT

The present application is based on International Application PCT/EP99/03344. Before calculation of the filing fee, please amend the above-referenced patent application as follows:

In the specification:

At page 80, line 11 at the end of the oligo rev sequence, replace "GLAG" with --GTAG--.

In the claims:

6. (Amended) A library according to [any of] claim[s] 1 [to 5] displayed on the surface of bacteriophage particles.

7. (Amended) A method of obtaining at least one [or more] peptide[s] containing an epitope immunologically cross-reactive with an epitope in the HVR1 of an HCV strain, the method including bringing into contact a library of peptides according to [any of] claim[s] 1 [to 5] and an antibody molecule able to bind said HVR1 of an HCV

strain, and selecting said at least one [or more] peptide[s] of the library able to bind said antibody molecule.

8. (Amended) A method according to claim 7 wherein [the] said at least one peptide [or peptides] selected contain an epitope immunologically cross-reactive with the HVR1 of a plurality of strains of HCV.

9. (Amended) A method according to claim 8 including bringing into contact a library of peptides according to [any of] claim[s] 1 [to 5] and a plurality of antibody molecules collectively able to bind the HVR1 of a plurality of strains of HCV.

11. (Amended) A method according to [any of] claim[s] 7 [to 10] wherein said library is displayed on the surface of bacteriophage particles, each particle containing nucleic acid encoding the peptide displayed on its surface.

14. (Amended) A method according to [any of] claim[s] 7 [to 13] wherein a peptide with the amino acid sequence of [a] said selected peptide is provided in isolated form.

17. (Amended) A method according to [any of] claim[s] 14 [to 16] wherein said at least one peptide with the amino acid sequence of a said selected peptide [said plurality of peptides or said mixture of plurality of peptides] in isolated form is provided by a process selected from the group consisting of expression from encoding nucleic acid and peptide synthesis.

19. (Amended) A method according to [any of] claim[s] 14 [to 18] wherein said at least one peptide with the amino acid sequence of a said selected peptide[, said plurality of peptides or said mixture of plurality of peptides] in isolated form is formulated into a composition including at least one additional component.

22. (Amended) A method according to [any of] claim[s] 7 [to 17] wherein the amino acid sequence of a said selected peptide is provided in a fusion with additional amino acids.

24. (Amended) A method according to claim 22 [or claim 23] wherein said fusion is formulated into a composition including at least one additional component.

31. (Amended) A method according to [any of] claim[s] 7 [to 30] wherein said at least one selected peptide has [or selected peptides each have] an amino acid sequence according to the following formula ("Formula II"):

Q T H T V G G Q A S H Q A S S L T S L F S P G A K Q N
T R G L S
R Q P

32. (Amended) A mixture of 108 different peptides obtainable from a library according to [any of] claim[s] 1 [to 6], wherein each of the 108 different peptides has an amino acid sequence according to the following formula ("Formula II"):

Q T H T V G G Q A S H Q A S S L T S L F S P G A K Q N
 T R G L S
 R Q P

35. (Amended) A composition according to claim 33 [or claim 34] including [any] at least one [or more] of the peptides G31, F78, R9, D6, M122 and H1 of which the amino acid sequences are shown in Figure 7(A).

39. (Amended) A composition according to [any of] claim[s] 33 [to 38] wherein [one or more of] said plurality of peptides is in a fusion with additional amino acids.

42. (Amended) A composition according to [any of] claim[s] 33 to 41] 39 including at least one additional component.

46. (Amended) A peptide obtainable from a library according to [any one of] claim[s] 1 [to 5].

49. (Amended) A composition including a peptide [according to any of claims 46 to 48] selected from the group consisting of

a) a peptide obtainable from a library as claimed in claim 1; and

2.11 QTHTVGGVOGROAHSLSLFSFGASON; and

D6 QTTTGGQVSHATHGLTGLFSLGPQOK; and

D18 QTHTTGGSASHQASGLTRLFSQGPSON; and

F63 QTHVVGGOOGROVSSLVSLFSPGASQK; and

G31 THTTVGGSVARQVHSLTGLFSPGPQOK; and

L13 QHTTVGGSQAHAAHSLTRLFSPGSSQN; and

M69 QTTVVGGSQARAAGLVLFSLSGSKQN; and

Z61 QTHVVGGVGROTSGLVGLFSPGSKQN; and

R9 OTTVVGGSSQSHTVRGLTSLFSPGASON; and
B26 TTTTGGQAGHOAHSLSLSPGASOK; and
B22 QTHVVGGVQSHOTSGLTSLFSPGASOK; and
B35 QTHTTGGVOGHOTSRLTSLFSPGPSON; and
D29 TTTTVGGQAAHOTHSLTSLFSPGAKON; and
D33 TTTTGGQOQSHTVHGLVGLFSPGSKON; and
E26 QTHTVGGVOAHTVRGLTSLFSPGSSON; and
F80 QTHTTGGQAGHTASSLTGLFSPGAKON; and
F19 OTTTVGGVASHOAHSLTGLFSPGAKOK; and
F78 QTHTTGGQAGHOAHSLSLGLFSPGAKON; and
H1 QTHTTGGVVGHATSGLTSLFSPGPSOK; and
L76 TTTTVGGQASHOTSSLTGLFSPGSKON; and
B24 TTTTVGGQASHTTSSLTGLFSPGASOK; and
M63 QTHTTGGVVSHOTRSLVGLFSPGPQON; and
M27 OTTTTGGVASHAAHRLTSLFSPGPQOK; and
M122 OTTTTGGSSASHAVSSLTGLFSPGSKON; and
M129 OTTVVGGSSAGHTASSLVGLFSPGSKON; and
M119 TTTTVGGQASHTTSSLTGLFSPGSOON; and
R5 QTHTTGGQASHOVSSLVSLFSPGAKOK; and
R6 TTTTGGQVGHOTSGLTGLFSPGAQON; and
R27 TTHVVGGSSASHAVRGLTSLFSPGSSON; and
B14 QTTVTGQASHTTSSLTGLFSPGASOK; and
B33 ATHATGGQAAHSTHSLTSLFSPGASOK; and
F81 QTHVTGGSAAHOTGGLTGLFSPGPKON; and
B18 OTTVVGGQASHVSRLTGLFSPGSSOK; and
E19 THTTGGQQAHTTSRLVSLFSPGASOK; and
L72 QTTTAAHTTSGLTGLFSPGAKON; and
D20 QTHVTGVAGQTSGLVSLFSPGSSON; and
D30 QGGVOGHTTSSLVGLFSPGSOON.

50. (Amended) A composition including a plurality of peptides according to [any of] claim[s] [46 to 48] 49.

51. (Amended) A composition according to claim 50 including 2 to about 10 different peptides [according to any of claims 46 to 48].

52. (Amended) A composition according to [any of] claim[s] [49 to 51] 50 wherein one or more of said peptides is in a fusion with additional amino acids.

55. (Amended) A composition according to [any of] claim[s] 49 [to 54] including at least one additional component.

58. (Amended) Nucleic acid encoding at least one peptide according to [any of] claim[s] 45 [to 48].

60. (Amended) Nucleic acid according to claim 58 [or claim 59] operably linked to regulatory sequences for expression of [the] said at least one encoded peptide [or peptides].

62. (Amended) A method for production of at least one peptide [or peptides] according to [any of] claim[s] 45 [to 48], the method including causing expression from nucleic acid [according to claim 60] encoding said peptide in a host cell.

64. (Amended) A method according to claim 62 [or claim 63] including isolation and[/or] purification of said at least one peptide [or peptides].

65. (Amended) A method according to [any of] claim[s] [62 to] 64 including formulating said at least one peptide [or peptides] into a composition including at least

one additional component.

68. (Amended) A method of obtaining at least one [or more] antibody molecule[s] containing a binding site able to bind an epitope in the HVR1 of a plurality of HCV strains, the method including bringing into contact a population of antibody molecules and a peptide according to [any of] claim[s] 45 [to 48], and selecting said at least one [or more] antibody molecule[s] of the population able to bind said peptide.

70. (Amended) A method according to claim 68 [or claim 69] wherein the peptides are provided in a fusion with additional amino acids.

71. (Amended) A method according to [any of] claim[s] [68 to] 70 wherein said at least one peptide [or plurality of peptides] is administered to a non-human mammal to bring it [or them] into contact with a population of antibody molecules produced by the mammal's immune system, [then] followed by isolation of said at least one [or more] antibody molecule[s] able to bind said peptide [or peptides is taken] from the mammal.

72. (Amended) A method according to [any of] claim[s] 68 [to 70] wherein [the] said at least one peptide [or peptides are] is administered to a non-human mammal to bring them into contact with a population of antibody molecules produced by the mammal's immune system, [then] followed by isolation of cells producing antibody molecules able to bind [the] said at least one peptide [or peptides

are taken] from the mammal.

73. (Amended) A method according to claim 72 wherein said antibody molecule(s) are [taken] isolated from said cells [or descendants thereof] producing said antibody molecules.

74. (Amended) A method according to [any of] claim[s] 71 to 73] 72 wherein the mammal is sacrificed.

75. (Amended) A method according to [any of] claim[s] 68 [to 70] wherein the population of antibody molecules is displayed on the surface of bacteriophage particles, each particle containing nucleic acid encoding the antibody molecule displayed on its surface.

76. (Amended) A method according to claim 75 wherein nucleic acid is taken from a bacteriophage particle displaying an antibody molecule able to bind said at least one peptide [or peptides].

77. (Amended) A method according to claim 76 including producing an antibody molecule by expression from nucleic acid with the sequence of nucleic acid taken from a bacteriophage particle displaying an antibody molecule able to bind said at least one peptide [or peptides].

78. (Amended) A method according to [any of] claim[s] [68 to] 77 wherein an antibody molecule able to bind said at least one peptide [or peptides] is provided in isolated form.

81. (Amended) A method according to [any of]

claim[s] 78 [to 80] wherein said at least one antibody molecule [, plurality of antibody molecules or mixture of plurality of antibody molecules] in isolated form is provided by expression from encoding nucleic acid.

82. (Amended) A method according to [any of] claim[s] 78 [to 81] wherein said at least one antibody molecule [, plurality of antibody molecules or mixture of plurality of antibody molecules] in isolated form is formulated into a composition including at least one additional component.

84. An antibody molecule obtained by a method according to [any of] claim[s] 68 [to 83].

85. (Amended) A method for raising antibodies in a mammal, said method comprising administering [Use of] a composition according to [any of] claim[s] 33 [to 44] [in the manufacture of a medicament for raising in] to a mammal, thereby stimulating production of antibodies able to bind HCV HVR1 epitopes.

86. (Amended) A method for raising antibodies in a mammal, said method comprising administering [Use of] a peptide according to [any of] claim[s] 45 [to 48] [in the manufacture of a medicament for raising in] to a mammal, thereby stimulating production of antibodies able to bind HCV HVR1 epitopes.

88. (Amended) A method for producing anti-HCV antibodies in a mammal, said method comprising expression of a [Use of] nucleic acid according to [any of] claim[s] 58 [to 60] in the manufacture of a medicament for raising

in a mammal antibodies able to bind HCV HVR1 epitopes.

89. (Amended) A method for increasing antibody levels in a mammal, comprising administering [Use of] an antibody molecule according to claim 84 [in the manufacture of a medicament for increasing in] to a mammal, thereby increasing the level of antibodies able to bind HCV HVR1 epitopes in said mammal.

90. (Amended) A method of raising in a mammal antibodies able to bind HCV HVR1 epitopes, the method including administering a composition according to [any of] claim[s] 33 [to 44] to the mammal.

91. (Amended) A method of raising in a mammal antibodies able to bind HCV HVR1 epitopes, the method including administering a peptide according to [any of] claim[s] 45 [to 48] to the mammal.

92. (Amended) A method of raising in a mammal antibodies able to bind HCV HVR1 epitopes, the method including administering a composition according to [any of] claim[s] 49 [to 57] to the mammal.

93. (Amended) A method of raising in a mammal antibodies able to bind HCV HVR1 epitopes, the method including administering nucleic acid according to [any of] claim[s] 58 [to 60] to the mammal.

95. (Amended) A method according to [any of] claim[s] 90 [to 94] which is prophylactic.

96. (Amended) A method according to [any of] claim[s] 90 [to 94] wherein the mammal has an HCV infection.

Please cancel claims 15, 16, 18, 59, 63, 69, 79, 80, and 87.

REMARKS

The purpose of this preliminary amendment is to rectify an apparent typographical error in the specification and to remove existing multiple dependencies from the claims. Specifically, at page 80, line 11, the last nucleotides of the reverse oligonucleotide primer for amplifying the E2 gene contain a typographical error, GLAG should be replaced with GTAG in keeping with the disclosure in the specification at page 80, lines 5-9.

Favorable consideration leading to prompt allowance of the present application is respectfully requested.

Respectfully submitted,
DANN, DORFMAN, HERRELL AND SKILLMAN
A Professional Corporation

By Kathleen D. Rigaut
Kathleen D. Rigaut, Ph.D., J.D.
PTO Registration No. 43,047

Telephone: (215) 563-4100
Facsimile: (215) 563-4044

MIMOTOPES OF HYPERVARIABLE REGION 1 OF THE
E2 GLYCOPROTEIN OF HCV AND USES THEREOF

The present invention is concerned with peptides, specifically
5 peptides which are mimotopes of the hypervariable region 1
(HVR1) of the putative envelope protein E2 of hepatitis C
virus (HCV). Employing a combination of techniques the
present inventors have devised a large number of peptides with
sequences based on consensus analysis of naturally occurring
10 HVR1 sequences and experimental determination of cross-
reactivity to antibodies against different isolates, none of
which peptides occurs in nature. The peptides are
individually useful in raising and obtaining antibodies, for
in vitro (e.g. diagnostic) and in vivo purposes, and libraries
15 of peptides are useful in identifying peptides of particular
cross-reactivity with antibodies able to bind a plurality of
HVR1's of different HCV strains. Peptides may be used in
themselves or as part of fusion proteins, for instance in
recombinant HCV E2 polypeptides, which may be incorporated
20 into recombinant HCV particles.

The HVR1 region of HCV is the most variable antigenic fragment
in the whole viral genome and is mainly responsible of the
large inter and intra-individual heterogeneity of the
25 infecting virus. It contains a principal neutralization

epitope and has been proposed as the major player in the mechanism of escape from host immune response. Since anti-HVR1 antibodies are the only species shown to possess protective activity up to date, the development of an efficient prevention therapy is a very difficult task.

In devising the present invention, the inventors approached the problem of the HVR1 variability by deriving a consensus profile from more than two hundred HVR1 sequences from different viral isolates and used this consensus as a template for generating a vast repertoire of synthetic HVR1 surrogates. These were provided as fusions to the major coat protein VIII of M13 bacteriophage for display on the surface of bacteriophage particles. This library was affinity selected using many different sera from infected patients. Phage were identified which displayed high frequency of reactivity with patients' sera, but not with sera from uninfected controls. The selected sequences were shown to bind serum antibodies cross-reacting with a large panel of peptides reproducing the HVR1 from natural HCV variants.

In these "mimotopes" was identified a sequence pattern responsible for the observed cross-reactivity. When injected in experimental animals, the mimotopes with the highest cross-reactivity induced antibodies able to recognise the same panel

of natural HVR1 variants.

Hepatitis C virus (HCV) is the major etiologic agent of both blood-transfusion-associated and sporadic non-A non-B hepatitis worldwide, with an estimated prevalence between 0.4 and 2% in the blood donor population (Choo et al., 1989). HCV infection leads to viral persistence and chronic disease in at least 70% of cases, among which a significant proportion eventually develops cirrhosis and hepatocellular carcinoma (for a review see H. Alter, 1995). In spite of the availability of reliable serological tests for HCV diagnosis, community-acquired infection is still common and causes significant morbidity and mortality worldwide (Mast and Alter, 1993). In addition, interferon treatment, which is the only anti-viral therapy available at the moment, is effective only in 20-30% of patients (Fried and Hoofnagle, 1995). Thus, development of an HCV vaccine represents a high priority project in the field.

The high frequency with which the virus establishes a persistent infection, despite a wide array of humoral and cell-mediated host immune responses, raised in the past some concerns about the existence of a protective immunity against HCV (Farci et al., 1992). As a matter of fact, protective immunity against challenge with homologous virus could be

induced by vaccination of chimpanzees (the only other species susceptible to HCV infection) using recombinant forms of the putative envelope proteins E1 and E2 (Choo et al., 1994).

However, it remains to be established how effective this

5 response would be against heterologous viral inocula.

HCV exists in the bloodstream of infected patients as a

quasispecies (Weiner et al., 1991; Martell et al., 1992;

Martell et al., 1994; Kurosaki et al., 1994; Bukh et al.,

10 1995) which fluctuates during the course of the disease mainly

as a result of immune pressure (Weiner et al., 1992; Kato et al., 1993; Kojima et al., 1994; Shimizu et al., 1994; van

Doorn et al., 1995; Weiner et al., 1995). The emerging view

is that chronic infection by HCV is not due to lack of humoral

15 or cellular responses, but rather to such responses being

rendered ineffective by the high mutation rate of the virus which leads to the emergence of escape variants.

The existence of neutralising antibodies and their role in

20 protection from viral infection was documented by ex vivo

neutralization of a pedigreed viral inoculum prior to

injection into chimpanzees (Farci et al., 1994). This

notwithstanding, neutralising antibodies were isolate-specific

and seemed to be able to block only viral variants which were

25 present before the onset of the corresponding humoral response

(Farci et al., 1994). Even if the specificity of such neutralising antibodies is not well defined, both immunological and molecular evidence indicate that epitopes recognised by neutralising antibodies are localised in the hypervariable region 1 (HVR1) of the HCV genome (Farci et al., 1994). This consists of the N-terminal 27 amino acids of the E2 glycoprotein, the most variable region of the whole HCV polyprotein (Weiner et al., 1991). Direct proof for the role of anti-HVR1 antibodies in virus clearance came recently from ex vivo neutralization experiments. A rabbit anti-HVR1 hyperimmune serum raised against the predominant variant of an infectious HCV inoculum abolished its infectivity in one chimp, and partially protected a second animal by blocking propagation of the major variant present in the inoculum (Farci et al., 1996).

Thus, the evidence is that the HVR1 contains a principal neutralization determinant for HCV, and that it should constitute an essential component of an acellular HCV vaccine if one could surmount the problem of its variability. Relevant to this issue is the observation that anti-HVR1 antibodies from human sera display some degree of cross-reactivity to different HVR1 variants (Scarselli et al., 1995).

WO94/26306 (Chiron Corporation) discloses an attempt at identifying a consensus sequence within the HVR1 of HCV, based on sequence comparison on the 90 strains said to have been known as of 12 May 1993. The disclosed formula is of a

5 peptide including the following sequence: aa1-aa2-aa3-aa4-aa5-aa6, wherein aa1 is S, G, A, D, K, R or T; aa2 is L, F, I, M or W; aa3 is F or L; aa4 is any amino acid; aa5 is any amino acid; and aa6 is G or A; with the proviso that the motif is not contained within a 31 amino acid sequence of a naturally occurring E2HV domain of an HCV isolate known as of May 12, 10 1993. In a further embodiment, aa7 is present and attached to aa6; aa7 being A, P or S. The 6 amino acid motif represents around 55,000 different sequence. The 7 amino acid motif represents around 165,000 different sequences.

15 Aspects of the present invention are based in part on a close inspection of the variability in HVR1 revealing that some positions of the HVR1 are less variable than others, suggesting that the actual structural, and immunological 20 variability is more limited than that suggested by the heterogeneity in primary sequence. The invention is concerned in various aspects with providing "synthetic variants" of the HCV HVR1 which are immunologically similar to a plurality, preferably a great number of natural HVR1 variants and, 25 therefore, may be used to induce neutralising antibodies which

cross-react with different HCV variants, preferably most or all. As explained further below, the formulae arrived at for peptides of the present invention differs from that provided in WO94/26306, and is based on actual cross-reactivity scoring rather than just sequence comparison.

Phage displayed peptide libraries offer the unique chance to rapidly survey large collections of peptidic sequences (10^8 or more) through a cyclic selection/rescue/amplification procedure. They allow identification of ligands for any type of ligate ranging from linear peptides to folded protein domains, and even carbohydrates (Cortese et al., 1994, Cortese et al., 1996). These ligands are true mimotopes as they do not necessarily share the same amino acid sequence of the original epitope, but they mimic its binding properties. A strategy for the identification of disease-specific phage-displayed mimotopes was reported previously, which avails itself only of clinically characterized sera from immune and non immune individuals (Folgori et al., 1994, hereby incorporated by reference). Furthermore, disease-specific mimotopes proved to be good immunogenic mimics of the natural antigen as they were able to induce a specific immune response to the natural antigen when injected into different animals (Folgori et al., 1994, and Meola et al., 1995, (both hereby incorporated by reference) Prezzi et al., 1996, Mecchia et

al., 1996). Thus, phage libraries may be used as a source of artificial ligands recognised by disease-specific antibodies, with the advantage that additional desirable features can be built-in, providing that they can be selected for during library enrichment.

In making the present invention, the inventors approached the problem of the HVR1 variability by generating a vast repertoire of HVR1 surrogates as fusion to the major coat protein (pVIII) of bacteriophage M13. Using the power of selection and many sera from clinically characterized HCV infected individuals peptides were isolated which revealed to be good antigenic and immunogenic mimics of a large number of naturally occurring HCV variants.

Experimental details are provided below.

In accordance with various aspects of the present invention there are provided libraries of peptides containing large numbers of different peptides, individual peptides which contain epitopes cross-reactive with a plurality of HCV HVR1 epitopes, and mixtures of different such peptides.

One aspect of the present invention provides a library of peptide conforming with the following consensus profile:

Q T H V T G G S A A R T T S G L T S L F S P G A S Q N
 T T T V V Q G H A A H S V G R L P K K
 R Q V S Q V R R R S S Q

Q

- 5 This profile represents a total of 9×10^7 individual sequences, i.e. a number very close to the upper practical limit (about 10^8) of current DNA cloning and transformation techniques. As described below, this consensus profile was used for the construction of a 27aa peptide library by cloning
- 10 a degenerated synthetic oligonucleotide as a fusion to the 5' end of the gene coding for the major coat protein (pVIII) in a phagemid vector for M13. The library was extensively screened using human sera, and more than one hundred different clones (mimotopes) were selected for their characteristic to
- 15 specifically recognise human anti HCV-HVR1 antibodies. Nearly all these mimotopes have different amino acid sequences and none of them could be found to correspond to published (up to January 98) natural HVR1.
- 20 In a preferred embodiment of a peptide library according to the present invention there are at least about 10^5 different peptides present, preferably at least about 10^6 different peptides, more preferably at least about 10^7 , e.g. about 9×10^7 different peptides.

A library of peptides may be displayed on the surface of bacteriophage, particularly filamentous bacteriophage such as fd or M13, for instance as fusions with the major coat protein (pVIII) of such bacteriophage. Phage display of peptides is

5 standard in the art and its power lies in the fact that bacteriophage particles are constructed so that packaged within each particle is nucleic acid encoding the peptide displayed on its surface. Following selection of phage particles displaying a peptide of interest, such as a peptide

10 able to bind one or more antibodies (e.g. antibodies able to bind a number of epitopes of HVR1 of different strains of HCV), the nucleic acid encoding the displayed peptide can be retrieved and used in production of further peptide with that amino acid sequence.

15 In the experimental work described below, the inventors tested mimotopes in a library according to the present invention with a panel of human sera, and individual mimotopes were characterised as having a different overall frequency of
20 reactivity with the sera. The 24 clones that only reacted with less than 3 sera were defined as "weak" while the 27 reacting with more than 11 sera were defined as "strong".

Statistical analysis of the consensus sequences of "strong"
25 and "weak" clones, lead to the discovery of a sequence motif

in the HVRI that is correlated with high frequency of reaction with human sera, crossreactivity with human anti HVRI antibodies and induction of highly crossreactive sera in experimental animals.

5

Peptides according to the present invention, and mixtures thereof, may be defined as follows, further explanation of which is given below in the experimental section:

10 (1) - A library of peptides fully described by the following formula ("Formula I"):

Q T H V T G G S A A R T T S G L T S L F S P G A S Q N

T T T V V Q G H A A H S V G R L P K K

15 R Q V S Q V R R R S S Q

Q

which may be written as

(aal)T(aa3)(aa4)(aa5)GG(aa8)(aa9)(aa10)(aa11)(aa12)(aa13)(aa14

20) (aa15)L(aa17)(aa18)LF(aa21)(aa22)G(aa24)(aa25)Q(aa27)

wherein aal is Q or T; aa3 is H, T or R; aa4 is V or T; aa5 is T or V; aa8 is S, V or Q; aa9 is A, Q or V; aa10 is A, G or S; aa11 is R or H; aa12 is T, A or Q; aa13 is T, A or V; aa14 is S, H or R; aa15 is G, S or R; aa17 is T or V; aa18 is S, G or
25 R; aa21 is S or R; aa22 is P, L, S or Q; aa24 is A, P or S;

aa25 is S, K or Q; aa27 is N or K.

(2) - 27 "strong" peptides obtainable from such a library are preferred peptides according to various aspects of the present invention, having an amino acid sequence as follows:

2.11 QT H TVGGVQG R QAHS LT S LF S P G A SQN
D6 QT T TTGGQVS H ATHGLT G LF S L G P QQK
D18 QT H TTGGSAS H QASGLT R LF S Q G P SQN
10 F63 QT H VVGGQQG R QVSSLV S LF S P G A SQK
G31 TT H TVGGSVA R QVHSLT G LF S P G P QQK
L13 QT H TVGGSQA H AAHSLT R LF S P G S SQN
M69 QT T VVGSQA R AAHGLV S LF S L G S KQN
Z61 QT H VVGGVQG R QTSGLV G LF S P G S KQN
15 R9 QT T VVGSQS H TVRGLT S LF S P G A SQN
B26 TT T TTGGQAG H QAHS LT S LF S P G A SQK
B22 QT H VVGGVQS H QTSGLT S LF S P G A SQK
B35 QT H TTGGVQG H QTSRLT S LF S P G P SQN
D29 TT T VVGGQAA H QTHSLT S LF S P G A KQN
20 D33 TT T TTGGQQS H TVHGLV G LF S P G S KQN
E26 QT H TVGGVQA H TVRGLT S LF S P G S SQN
F80 QT H TTGGQAG H TASSLT G LF S P G A KQN
F19 QT T TVGGVAS H QAHS LT G LF S P G A KQK
F78 QT H TTGGQAG H QAHS LT G LF S P G A KQN
25 H1 QT H TTGGVVG H ATSGLT S LF S P G P SQK

L76 TT T TVGGQAS H QTSSLT G LF S P G S KQN
 M27 QT T TTGGVAS H AAHRLT S LF S P G P QOK
 M122 QT T TTGGSAS H AVSSLT G LF S P G S KQN
 M129 QT T VVGGSAG H TASSLV G LF S P G S KQN
 5 M119 TT T TVGGQAS H TTSSLT G LF S P G S QON
 R5 QT H TTGGQAS H QVSSLV S LF S P G A QOK
 R6 TT T TTGGQVG H QTSGLT G LF S P G A QON
 R27 TT H VVGGSAS H AVRGLT S LF S P G S SQN

10

Further preferred peptides according to the present invention have any of the following sequences:

B14 QT T VTG_QAS H TTSSLT G LF S P G A SQK
 15 B33 aT H aTGGQAA H STHSLT S LF S P G A SQK
 F81 QT H VTGSAA H QTgGLT G LF S P G P KQN
 B18 QT T VVGQAS H _VSRLT G LF S P G S SQK
 L72 QT T T____AA H TTSGLT G LF S P G A KQN
 D20 QT H VTG_VAG R QTSGLV S LF S P G S SQN
 20 D30 Q_ _ _GGVQG H TTSSLV G LF S P G S QON
 E19 TT H T_GGQQA H TTSRLV S LF S P G A SQK
 B24 TT T TVGGQAS H TTSSLT G LF S P G A SQK
 M63 QT H TTGGVVS H QTRSLV G LF S P G P QON

25 The lower case letters are used to identify amino acid

residues that vary from Formula 1, while the underlined spaces are included to signify deletions compared with Formula 1, though the flanking amino acids are of course contiguous in the relevant peptides.

5

These are variants of peptides obtainable from a library in accordance with the present invention, not themselves conforming with Formula I. They were identified in the course of the experiments identified below and originated by PCR errors during library amplification. (See Materials and Methods, "Construction of the HVR1 library".)

(3) - A "strong consensus" ("Formula II"), derived from the consensus of the highly cross-reactive peptides of (2) above.

The statistical analysis of the frequencies of aa in any position in the 27 "strong" in comparison with the frequency in 25 "weak" is shown in Table II, and discussed further below in the experimental section.

Formula II:

25 QT(aa3)TVGGQQS(aa11)QVHSLT(aa18)LF(aa21)(aa22)G(aa24)SQN

where: aa3 is H or T; aa11 is H or R; aa18 is G, S or R; aa21 is S; aa22 is P, L or Q; aa24 is A, S or P;

which may also be written:

QT H TVGGQAS H QASSLT S LF S P G A KQN

T R G L S
R Q P

Residues in italics are included because although they have low frequencies they are found in some of the best reactive mimotopes tested (highlighted with an asterisk among the 27 "strong" peptides at II above.

The 27 mimotopes used to derive Formula II are not in it.

108 peptides conform to Formula II and each is an aspect of the invention. The sequences are:

1 QTHTV GGQAS HQASS LTSLF SPGAK QN

2 QTHTV GGQAS HQASS LTSLF SPGSK QN

3 QTHTV GGQAS HQASS LTSLF SPGPK QN

4 QTHTV GGQAS HQASS LTSLF SLGAK QN

5 QTHTV GGQAS HQASS LTSLF SLGSK QN

6 QTHTV GGQAS HQASS LTSLF SLGPK QN

7 QTHTV GGQAS HQASS LTSLF SQGAK QN

8 QTHTV GQAS HQASS LTSLF SQGSK QN
9 QTHTV GQAS HQASS LTSLF SQGPK QN
10 QTHTV GQAS HQASS LTGLF SPGAK QN
11 QTHTV GQAS HQASS LTGLF SPGSK QN
5 12 QTHTV GQAS HQASS LTGLF SPGPK QN
13 QTHTV GQAS HQASS LTGLF SLGAK QN
14 QTHTV GQAS HQASS LTGLF SLGSK QN
15 QTHTV GQAS HQASS LTGLF SLGPK QN
16 QTHTV GQAS HQASS LTGLF SQGAK QN
10 17 QTHTV GQAS HQASS LTGLF SQGSK QN
18 QTHTV GQAS HQASS LTGLF SQGPK QN
19 QTHTV GQAS HQASS LTRLF SPGAK QN
20 QTHTV GQAS HQASS LTRLF SPGSK QN
21 QTHTV GQAS HQASS LTRLF SPGPK QN
15 22 QTHTV GQAS HQASS LTRLF SLGAK QN
23 QTHTV GQAS HQASS LTRLF SLGSK QN
24 QTHTV GQAS HQASS LTRLF SLGPK QN
25 QTHTV GQAS HQASS LTRLF SQGAK QN
26 QTHTV GQAS HQASS LTRLF SQGSK QN
20 27 QTHTV GQAS HQASS LTRLF SQGPK QN
28 QTHTV GQAS RQASS LTSLF SPGAK QN
29 QTHTV GQAS RQASS LTSLF SPGSK QN
30 QTHTV GQAS RQASS LTSLF SPGPK QN
31 QTHTV GQAS RQASS LTSLF SLGAK QN
25 32 QTHTV GQAS RQASS LTSLF SLGSK QN

33 QTHTV GQAS RQASS LTSLF SLGPK QN
34 QTHTV GQAS RQASS LTSLF SQGAK QN
35 QTHTV GQAS RQASS LTSLF SQGSK QN
36 QTHTV GQAS RQASS LTSLF SQGPK QN
5 37 QTHTV GQAS RQASS LTGLF SPGAK QN
38 QTHTV GQAS RQASS LTGLF SPGSK QN
39 QTHTV GQAS RQASS LTGLF SPGPK QN
40 QTHTV GQAS RQASS LTGLF SLGAK QN
41 QTHTV GQAS RQASS LTGLF SLGSK QN
10 42 QTHTV GQAS RQASS LTGLF SLGPK QN
43 QTHTV GQAS RQASS LTGLF SQGAK QN
44 QTHTV GQAS RQASS LTGLF SQGSK QN
45 QTHTV GQAS RQASS LTGLF SQGPK QN
46 QTHTV GQAS RQASS LTRLF SPGAK QN
15 47 QTHTV GQAS RQASS LTRLF SPGSK QN
48 QTHTV GQAS RQASS LTRLF SPGPK QN
49 QTHTV GQAS RQASS LTRLF SLGAK QN
50 QTHTV GQAS RQASS LTRLF SLGSK QN
51 QTHTV GQAS RQASS LTRLF SLGPK QN
20 52 QTHTV GQAS RQASS LTRLF SQGAK QN
53 QTHTV GQAS RQASS LTRLF SQGSK QN
54 QTHTV GQAS RQASS LTRLF SQGPK QN
55 QTTTV GQAS HQASS LTSLF SPGAK QN
56 QTTTV GQAS HQASS LTSLF SPGSK QN
25 57 QTTTV GQAS HQASS LTSLF SPGPK QN

58 QTTTV GGQAS HQASS LTSLF SLGAK QN
59 QTTTV GGQAS HQASS LTSLF SLGSK QN
60 QTTTV GGQAS HQASS LTSLF SLGPK QN
61 QTTTV GGQAS HQASS LTSLF SQGAK QN
5 62 QTTTV GGQAS HQASS LTSLF SQGSK QN
63 QTTTV GGQAS HQASS LTSLF SQGPK QN
64 QTTTV GGQAS HQASS LTGLF SPGAK QN
65 QTTTV GGQAS HQASS LTGLF SPGSK QN
66 QTTTV GGQAS HQASS LTGLF SPGPK QN
10 67 QTTTV GGQAS HQASS LTGLF SLGAK QN
68 QTTTV GGQAS HQASS LTGLF SLGSK QN
69 QTTTV GGQAS HQASS LTGLF SLGPK QN
70 QTTTV GGQAS HQASS LTGLF SQGAK QN
71 QTTTV GGQAS HQASS LTGLF SQGSK QN
15 72 QTTTV GGQAS HQASS LTGLF SQGPK QN
73 QTTTV GGQAS HQASS LTRLF SPGAK QN
74 QTTTV GGQAS HQASS LTRLF SPGSK QN
75 QTTTV GGQAS HQASS LTRLF SPGPK QN
76 QTTTV GGQAS HQASS LTRLF SLGAK QN
20 77 QTTTV GGQAS HQASS LTRLF SLGSK QN
78 QTTTV GGQAS HQASS LTRLF SLGPK QN
79 QTTTV GGQAS HQASS LTRLF SQGAK QN
80 QTTTV GGQAS HQASS LTRLF SQGSK QN
81 QTTTV GGQAS HQASS LTRLF SQGPK QN
25 82 QTTTV GGQAS HQASS LTSLF SPGAK QN

83 QTTTV GGQAS RQASS LTSLF SPGSK QN
84 QTTTV GGQAS RQASS LTSLF SPGPK QN
85 QTTTV GGQAS RQASS LTSLF SLGAK QN
86 QTTTV GGQAS RQASS LTSLF SLGSK QN
5 87 QTTTV GGQAS RQASS LTSLF SLGPK QN
88 QTTTV GGQAS RQASS LTSLF SQGAK QN
89 QTTTV GGQAS RQASS LTSLF SQGSK QN
90 QTTTV GGQAS RQASS LTSLF SQGPK QN
91 QTTTV GGQAS RQASS LTGLF SPGAK QN
10 92 QTTTV GGQAS RQASS LTGLF SPGSK QN
93 QTTTV GGQAS RQASS LTGLF SPGPK QN
94 QTTTV GGQAS RQASS LTGLF SLGAK QN
95 QTTTV GGQAS RQASS LTGLF SLGSK QN
96 QTTTV GGQAS RQASS LTGLF SLGPK QN
15 97 QTTTV GGQAS RQASS LTGLF SQGAK QN
98 QTTTV GGQAS RQASS LTGLF SQGSK QN
99 QTTTV GGQAS RQASS LTGLF SQGPK QN
100 QTTTV GGQAS RQASS LTRLF SPGAK QN
101 QTTTV GGQAS RQASS LTRLF SPGSK QN
20 102 QTTTV GGQAS RQASS LTRLF SPGPK QN
103 QTTTV GGQAS RQASS LTRLF SLGAK QN
104 QTTTV GGQAS RQASS LTRLF SLGSK QN
105 QTTTV GGQAS RQASS LTRLF SLGPK QN
106 QTTTV GGQAS RQASS LTRLF SQGAK QN
25 107 QTTTV GGQAS RQASS LTRLF SQGSK QN

108 QTTTV GQAS RQASS LTRLF SQGPK QN

(4) - A further library of peptides within the library of Formula I, including the sequences of Formula II, defining 2.5×10^6 sequences and conforming to the following Formula III:

Q T H T V G G Q A S H Q A S S L T S L F S P G A K Q N
T T V T S Q G A T H G V G S S K
V V A T V R R P Q

10

15

20

25

A peptide according to the present invention may be provided in a fusion with additional amino acids. Additional amino acids may be fused at one or both of the N-terminus and the C-terminus of the peptide. The additional amino acids may be an amino acid sequence that is not a fragment of HCV E2 protein, or may be an amino acid sequence that is part of that protein. Furthermore, a fusion including a peptide according to the present invention may include a HCV E2/NS1 protein with the peptide amino acid sequence in the HVR1 position, i.e. such that the mimotope HVR1 peptide of the invention substitutes for the natural HVR1 sequence. Another way of expressing this is to refer to a "recombinant HCV E2/NS1 protein in which a peptide of the present invention is substituted for the HVR1". As noted below, nucleic acid encoding peptides and polypeptides, including fusions, according to invention are

provided as further aspects of the invention, as is a recombinant HCV genome including a nucleotide sequence encoding a peptide of the invention, for instance within the E2/NS1 coding sequence to provide for production of a

- 5 recombinant HCV E2/NS1 protein in which a peptide of the invention is substituted for the HVR1 and incorporation of the recombinant protein into an assembled HCV particle. A recombinant HCV particle including one or more peptides or polypeptides as disclosed herein is provided as a further
10 aspect of the present invention.

- Generally, a peptide according to the present invention is immunogenic or able to raise an immune response on administration to an individual or includes an epitope
15 immunologically cross-reactive with an epitope of a plurality of strains of HCV.

- Another aspect of the present invention provides a method of obtaining one or more peptides containing an epitope
20 immunologically cross-reactive with an epitope in the HVR1 of an HCV strain, the method including bringing into contact a library of peptides as disclosed and an antibody molecule able to bind said HVR1 of an HCV strain, and selecting one or more peptides of the library able to bind said antibody molecule.

The peptide or peptides selected may contain an epitope immunologically cross-reactive with the HVR1 of a plurality of strains of HCV.

5 Such a method may include bringing into contact a library of peptides and a plurality of antibody molecules collectively able to bind the HVR1 of a plurality of strains of HCV. In one embodiment, said plurality of antibody molecules is derived from sera of individuals infected with HCV.

10

As noted, said library may be displayed on the surface of bacteriophage particles, each particle containing nucleic acid encoding the peptide displayed on its surface. Following selection, nucleic acid may be taken from a bacteriophage particle displaying a said selected peptide. Nucleic acid with the sequence of nucleic acid taken from a bacteriophage particle displaying a said selected peptide may be used in production of such a peptide by means of expression (using recombinant DNA technology as standard in the art and

15
20 discussed further below).

A peptide with the amino acid sequence of a said selected peptide may provided in isolated form, e.g. after its production by expression from encoding nucleic acid. As noted further below, one or more peptides in accordance with the

25

present invention may be provided by peptide synthesis.

A plurality of peptides each with the amino acid sequence of a different selected peptide may provided in isolated form,
5 individually or in a mixture.

A selected peptide or selected peptides may each have an amino acid sequence according to the Formula II given above. All 108 of the different peptides according to Formula II may be
10 provided as a mixture, and furthermore each individually represents an aspect of the present invention. Each peptide of these 108 has a high probability of being cross-reactive with epitopes in the HVR1 of the E2/NS2 protein of a number of strains of HCV, and therefore is particularly useful for
15 obtaining antibodies or otherwise raising an immune response.

A composition according to the present invention may include a plurality of peptides obtainable from a mixture of the 108 peptides of Formula II. Such a composition may include from 2
20 to about 20, 15, 10, 9, 8, 7, 6, 5, 4 or 3 different peptides obtainable from said mixture.

Preferred peptides which may be provided in a mixture or individually include those denoted G31, F78, R9, D6, M122 and
25 H1 of which the amino acid sequences are shown in Figure 7(A).

Preferred mixtures included peptides R9, F78, H1 and D6 ("MIX1"), include peptides M122 and G31 ("MIX2"), or include peptides G31, F78, R9, D6, M122 and H1 ("MIX3").

- 5 Immunological cross-reactivity of each peptide of the invention with the HVR1 of HCV strains can be assessed experimentally, as exemplified below. Various mixtures of these peptides may also be made and similarly tested, again as experimentally exemplified below.

10

Linear or branched (e.g. MAP) peptides and polypeptides (e.g. fusion molecules including a peptide as discussed) in accordance with the present invention may be made using any of a variety of techniques at the disposal of the ordinary person skilled in the art.

15

Linear or branched peptides may be synthesized using standard peptide chemistry such as by the common method employing Fmoc (Fluorenylmethyl-oxycarbonyl)-t-Bu (tert-butyl), as described in Atherton and Sheppard (1989), *Solid Phase Peptide Synthesis, a Practical Approach*, IRL Press, Oxford.

20

A convenient way of producing a peptide or polypeptide according to the present invention is to express nucleic acid encoding it, by use of the nucleic acid in an expression

25

system.

Accordingly, the present invention also encompasses a method of making a peptide or polypeptide (as disclosed), the method including expression from nucleic acid encoding the peptide or polypeptide (generally nucleic acid according to the invention). This may conveniently be achieved by growing a host cell in culture, containing such a vector, under appropriate conditions which cause or allow expression of the polypeptide. Peptides and polypeptides may also be expressed in *in vitro* systems, such as reticulocyte lysate.

Polynucleotides encoding peptides and polypeptides according to the present invention represent further aspects of the invention.

In one aspect there is provided a polynucleotide encoding a peptide as disclosed. In a further aspect, there is provided a polynucleotide encoding a fusion as disclosed, particularly a HCV E2/NS1 protein including the amino acid sequence of a peptide of the invention in the HVR1 position. In a further aspect, there is provided a recombinant HCV genome including a nucleotide sequence encoding a peptide according to the invention or a fusion as disclosed, particularly a HCV E2/NS1 protein with the relevant peptide amino acid sequence in the

HVR1 position.

In a still further aspect, a polynucleotide is provided which includes a plurality of nucleotide sequences encoding peptides
5 or polypeptides according to the invention. This allows for production of a mixture of peptides or polypeptides in a single expression reaction.

Nucleic acid encoding a peptide or polypeptide according to
10 the present invention may be used in nucleic acid immunisation in order to raise an immune response in a mammal, such as a human individual for a therapeutic or prophylactic purpose, or a non-human mammal for such a purpose or in order to produce antibodies for subsequent manipulation and/or use (e.g. in
15 diagnostic or therapeutic contexts as discussed further below.)

Nucleic acid encoding a peptide or polypeptide according to the present invention may be used in a method of gene therapy,
20 in prevention and/or treatment of HCV infection. This requires use of suitable regulatory elements for expression and a suitable vector for deliver of the expression unit (coding sequence and regulatory elements) to host cells. A variety of vectors, both viral vectors and plasmid vectors,
25 are known in the art, see e.g. US Patent No. 5,252,479 and WO

93/07282. In particular, a number of viruses have been used as gene transfer vectors, including papovaviruses, such as SV40, vaccinia virus, herpesviruses, including HSV and EBV, and retroviruses. Many gene therapy protocols in the prior art have used disabled murine retroviruses. A variety of adenovirus and adeno-associated viral vectors have been developed. Alternatives to viral vectors include transfer mediated by liposomes and direct DNA uptake and receptor-mediated DNA transfer.

Host cells containing nucleic acid encoding a peptide or polypeptide (or mixture thereof) according to the present invention may themselves be used in therapeutic or prophylactic treatment of individuals for or against HCV infection (i.e. therapeutic treatment of an individual with an HCV infection or prophylactic treatment of an individual prior to HCV infection).

Nucleic acid is generally provided as DNA or RNA, though may include one or more nucleotide analogues, and may be wholly or partially synthetic. Nucleic acid molecules and vectors according to the present invention may be provided in isolated and/or purified form, e.g. in substantially pure or homogeneous form. The term "isolate" may be used to reflect all these possibilities. Where a DNA sequence is specified,

e.g. with reference to a figure, unless context requires otherwise the RNA equivalent, with U substituted for T where it occurs, is encompassed.

- 5 Where it is desired to express a peptide or polypeptide from encoding nucleic acid, the nucleic acid includes appropriate regulatory control sequences. Suitable vectors can be chosen or constructed, containing appropriate regulatory sequences, including promoter sequences, terminator fragments,
- 10 polyadenylation sequences, enhancer sequences, marker genes and other sequences as appropriate. Vectors may be plasmids, viral e.g. 'phage, or phagemid, as appropriate. For further details see, for example, Molecular Cloning: a Laboratory Manual: 2nd edition, Sambrook et al., 1989, Cold Spring
- 15 Harbor Laboratory Press. Many known techniques and protocols for manipulation of nucleic acid, for example in preparation of nucleic acid constructs, mutagenesis, sequencing, introduction of DNA into cells and gene expression, and analysis of proteins, are described in detail in Current
- 20 Protocols in Molecular Biology, Ausubel et al. eds., John Wiley & Sons, 1992.

Systems for cloning and expression of a polypeptide in a variety of different host cells are well known. Suitable host

25 cells include bacteria, eukaryotic cells such as mammalian and

yeast, and baculovirus systems. Mammalian cell lines available in the art for expression of a heterologous polypeptide include Chinese hamster ovary cells, HeLa cells, baby hamster kidney cells, COS cells and many others. A

5 common, preferred bacterial host is *E. coli*.

A further aspect of the present invention provides a host cell containing nucleic acid as disclosed herein. The nucleic acid of the invention may be integrated into the genome (e.g.

10 chromosome) of the host cell. Integration may be promoted by inclusion of sequences which promote recombination with the genome, in accordance with standard techniques. The nucleic acid may be on an extra-chromosomal vector within the cell.

15 A still further aspect provides a method which includes introducing the nucleic acid into a host cell. The introduction, which may (particularly for *in vitro* introduction) be generally referred to without limitation as "transformation", may employ any available technique. For
20 eukaryotic cells, suitable techniques may include calcium phosphate transfection, DEAE-Dextran, electroporation, liposome-mediated transfection and transduction using retrovirus or other virus, e.g. vaccinia or, for insect cells, baculovirus. For bacterial cells, suitable techniques may
25 include calcium chloride transformation, electroporation and

transfection using bacteriophage. As an alternative, direct injection of the nucleic acid could be employed. Marker genes such as antibiotic resistance or sensitivity genes may be used in identifying clones containing nucleic acid of interest, as
5 is well known in the art.

The introduction may be followed by causing or allowing expression from the nucleic acid, e.g. by culturing host cells (which may include cells actually transformed although more
10 likely the cells will be descendants of the transformed cells) under conditions for expression of the gene, so that the encoded peptide or polypeptide is produced. If the peptide or polypeptide is expressed coupled to an appropriate signal leader peptide it may be secreted from the cell into the
15 culture medium. Following production by expression, a peptide or polypeptide may be isolated and/or purified from the host cell and/or culture medium, as the case may be, and subsequently used as desired, e.g. in the formulation of a composition which may include one or more additional
20 components, such as a pharmaceutical composition which includes one or more pharmaceutically acceptable excipients, vehicles or carriers (e.g. see below).

A peptide or polypeptide according to the present invention
25 may be used as an immunogen or otherwise in obtaining binding

antibodies. Antibodies are useful in purification and other manipulation of polypeptides and peptides, diagnostic screening and therapeutic contexts, including passive immunisation. This is discussed further below.

5

According to a further aspect of the present invention there is provided a method of obtaining one or more antibody molecules containing a binding site able to bind an epitope in the HVR1 of a plurality of HCV strains, the method including
10 bringing into contact a population of antibody molecules and a peptide according to the present invention, and selecting one or more antibody molecules of the population able to bind said peptide.

15 The method may involve bringing the population of antibodies into contact with a plurality of peptides according to the invention.

As noted, the peptides may be provided in a fusion with
20 additional amino acids.

The peptide or peptides may be administered to a non-human mammal to bring them into contact with a population of antibody molecules produced by the mammal's immune system,
25 then one or more antibody molecules able to bind the peptide

or peptides may be taken from the mammal, or cells producing such antibody molecules may be taken from the mammal.

The mammal may be sacrificed.

5

If cells are taken from the mammal, antibody molecules may be taken from said cells or descendants thereof. Such descendants in particular may include hybridoma cells.

- 10 Instead or as well as immunising an animal, a method of obtaining antibodies as disclosed may involve displaying the population of antibody molecules on the surface of bacteriophage particles, each particle containing nucleic acid encoding the antibody molecule displayed on its surface.
- 15 Nucleic acid may be taken from a bacteriophage particle displaying an antibody molecule able to bind a peptide or peptides of interest, for manipulation and/or use in production of the encoded antibody molecule or a derivative thereof (e.g. a fusion protein, a molecule including a
- 20 constant region or other amino acids, and so on). Instead of using bacteriophage for display, ribosomes or polysomes may be used, e.g. as disclosed in US-A-5643768, US-A-5658754, WO95/11922.

25 Antibody molecules may be provided in isolated form, either

individually or in a mixture. A plurality of antibody molecules may be provided in isolated form.

Preferred antibodies according to the invention are isolated,

- 5 in the sense of being free from contaminants such as antibodies able to bind other polypeptides and/or free of serum components. Monoclonal antibodies are preferred for some purposes, though polyclonal antibodies are within the scope of the present invention. Indeed, polyclonal mixtures
- 10 able to bind one or more peptides or polypeptides according to the present invention are preferred in some embodiments, as discussed. Thus, the present invention in a further aspect is directed to a mixture of different antibodies able to bind one or more peptides or polypeptides according to the invention.
- 15 Such a mixture may be provided in a composition including at least one additional component, such as a pharmaceutically acceptable excipient or vehicle.

The present invention also extends to methods of obtaining

- 20 and/or raising antibodies to one or more peptides or polypeptides of the invention. Such methods may include administering a peptide or polypeptide or mixture of peptides or polypeptides to a mammal in order to raise an antibody response. In a therapeutic or prophylactic context the mammal
- 25 may be human or non-human. For the production of antibodies

or antibody-producing cells to be isolated and used for any of a variety of purposes, a step of sacrificing a non-human mammal may be included. Such a non-human mammal may be for example mouse, rat, rabbit, dog, cat, pig, horse, donkey, 5 goat, sheep, camel, Old World monkey, chimpanzee or other primate. Antibodies may be obtained from immunised animals using any of a variety of techniques known in the art, and screened, preferably using binding of antibody to peptide or polypeptide of interest. For instance, Western blotting 10 techniques or immunoprecipitation may be used (Armitage et al, Nature, 357:80-82, 1992).

The production of polyclonal and monoclonal antibodies is well established in the art. Monoclonal antibodies can be 15 subjected to the techniques of recombinant DNA technology to produce other antibodies or chimeric molecules which retain the specificity of the original antibody. Such techniques may involve introducing DNA encoding the immunoglobulin variable region, or the complementarity determining regions (CDRs), of 20 an antibody to the constant regions, or constant regions plus framework regions, of a different immunoglobulin. See, for instance, EP-A-184187, GB-A-2188638 or EP-A-239400. Humanised antibodies in which CDRs from a non-human source are grafted onto human framework regions, typically with the alteration of 25 some of the framework amino acid residues, to provide

antibodies which are less immunogenic than the parent non-human antibodies, are also included within the present invention. A hybridoma producing a monoclonal antibody according to the present invention may be subject to genetic mutation or other changes, which may or may not alter the binding specificity of antibodies produced. Cloning and expression of chimeric antibodies are described in EP-A-0120694 and EP-A-0125023.

- 10 As an alternative or supplement to immunising a mammal with a peptide, an antibody specific for a protein may be obtained from a recombinantly produced library of expressed immunoglobulin variable domains, e.g. using bacteriophage which display functional immunoglobulin binding domains on
- 15 their surfaces - for instance see WO92/01047 - or ribosomes/polysomes as noted above. The library may be naive, that is constructed from sequences obtained from an organism which has not been immunised with any of the proteins (or fragments), or may be one constructed using sequences obtained
- 20 from an organism which has been exposed to the antigen of interest.

Antibodies according to the present invention may be modified in a number of ways. Indeed the term "antibody" should be

25 construed as covering any binding substance having a binding

domain with the required specificity. Thus the invention covers antibody fragments, derivatives, functional equivalents and homologues of antibodies, including synthetic molecules and molecules whose shape mimics that of an antibody enabling
5 it to bind an antigen or epitope.

Example antibody fragments, capable of binding an antigen or other binding partner are the Fab fragment consisting of the VL, VH, Cl and CH1 domains; the Fd fragment consisting of the
10 VH and CH1 domains; the Fv fragment consisting of the VL and VH domains of a single arm of an antibody; the dAb fragment which consists of a VH domain; isolated CDR regions and F(ab')₂ fragments, a bivalent fragment including two Fab fragments linked by a disulphide bridge at the hinge region.
15 Single chain Fv fragments are also included.

Hybridomas capable of producing antibody with desired binding characteristics are within the scope of the present invention, as are host cells, eukaryotic or prokaryotic, containing
20 nucleic acid encoding antibodies (including antibody fragments) and capable of their expression. The invention also provides methods of production of the antibodies including growing a cell capable of producing the antibody under conditions in which the antibody is produced, and
25 preferably secreted.

The reactivities of antibodies on a sample (e.g. in a diagnostic test) may be determined by any appropriate means. Tagging with individual reporter molecules is one possibility. The reporter molecules may directly or indirectly generate detectable, and preferably measurable, signals. The linkage of reporter molecules may be directly or indirectly, covalently, e.g. via a peptide bond or non-covalently. Linkage via a peptide bond may be as a result of recombinant expression of a gene fusion encoding antibody and reporter molecule.

One favoured mode is by covalent linkage of each antibody with an individual fluorochrome, phosphor or laser dye with spectrally isolated absorption or emission characteristics. Suitable fluorochromes include fluorescein, rhodamine, phycoerythrin and Texas Red. Suitable chromogenic dyes include diaminobenzidine.

Other reporters include macromolecular colloidal particles or particulate material such as latex beads that are coloured, magnetic or paramagnetic, and biologically or chemically active agents that can directly or indirectly cause detectable signals to be visually observed, electronically detected or otherwise recorded. These molecules may be enzymes which catalyse reactions that develop or change colours or cause

changes in electrical properties, for example. They may be molecularly excitable, such that electronic transitions between energy states result in characteristic spectral absorptions or emissions. They may include chemical entities used in conjunction with biosensors. Biotin/avidin or biotin/streptavidin and alkaline phosphatase detection systems may be employed.

The mode of determining binding is not a feature of the present invention and those skilled in the art are able to choose a suitable mode according to their preference and general knowledge.

Antibodies according to the present invention may be used in screening for the presence of a peptide or polypeptide, for example in a test sample containing cells or cell lysate as discussed, and may be used in purifying and/or isolating a peptide or polypeptide according to the present invention, for instance following production of the polypeptide by expression from encoding nucleic acid therefor.

Antibodies are also useful in prophylaxis, by way of passive immunisation, and in therapy. Where antibodies are to be administered, it may be preferable to include a mixture of antibodies, such as antibodies collectively cross-reactive

with a plurality of peptides according to the present invention.

Antibodies which bind a peptide in accordance with the present

- 5 invention may themselves be used as immunogens in the production of anti-idiotypic antibodies. These may be used to mimic a peptide epitope in raising an immune response in an individual, e.g. for therapeutic and/or prophylactic purposes.

- 10 An antibody may be provided in a kit, which may include instructions for use of the antibody, e.g. in determining the presence of a particular substance in a test sample. One or more other reagents may be included, such as labelling molecules, buffer solutions, elutants and so on. Reagents may
15 be provided within containers which protect them from the external environment, such as a sealed vial.

Diagnostic methods make use of biological samples from individuals that may contain one or more HCV strains.

- 20 Examples of biological samples include fluid such as blood, plasma, serum, urine and saliva, and tissue samples.

There are various methods for determining the presence or absence in a test sample of a particular peptide or

- 25 polypeptide, including methods wherein the polypeptide to be

detected is an antibody.

A sample may be tested for the presence of a specific binding member such as an antibody (or mixture of antibodies) directed
5 to one or more peptides of the invention.

Peptides according to the present invention may be used to determine the presence or absence of antibodies against HCV strains in test samples, by assessment of binding the peptides
10 to anti-HCV E2HVR1 antibodies if present in the sample.

In theory it may be possible to identify the presence in a sample of a binding partner for a specific binding member such as an antibody (or mixture of antibodies) directed to one or
15 more peptides of the invention. However, to date no-one has succeeded in isolating HCV virions from a human sample. In the future, should it prove possible to identify HCV virions in human samples and/or detect such virions immunologically, peptides of the invention and particularly antibodies directed
20 thereto will be useful in such detection.

For detection of antibodies to HCV, a biological or other sample may be tested by being contacted with one or more peptides of the invention under appropriate conditions for
25 specific binding, before binding is determined, for instance

using a reporter system as discussed. Where a panel of peptides is used, different reporting labels may be employed for each peptide so that binding of each can be determined.

5 A specific binding member such as a peptide may be used to isolate and/or purify its binding partner antibody from a test sample, to allow for sequence and/or biochemical analysis of the antibody. Amino acid sequencing is routine in the art using automated sequencing machines.

10

A typical immunoassay may involve incubating a test sample with peptides according to the invention under conditions to allow formation of immune complexes if an appropriate antibody is present in the sample, and detecting the presence or

15 absence of immune complex.

As noted, although not technically feasible at the moment, in principle antibodies according to the present invention may be used to determine the presence or absence of HCV strains in
20 test samples, by assessment of binding of the antibodies to E2HVR1 epitopes if present in the sample.

A typical immunoassay may involve incubating a test sample with peptides or anti-idiotypic antibodies according to the
25 invention under conditions to allow formation of immune

complexes if an appropriate antibody is present in the sample, and detecting the presence or absence of immune complex.

A sample may be tested for the presence of an antibody

- 5 directed to one or more peptides of the invention, using one or more such peptides (or polypeptide including such peptide) or one or more anti-idiotypic antibodies.

A biological or other sample may be tested by being contacted

- 10 with a peptide or polypeptide or anti-idiotypic antibody under appropriate conditions for specific binding, before binding is determined, for instance using a reporter system as discussed.

The detection of formation of a binding complex in an

- 15 immunoassay in accordance with the present invention may be performed using any available technique without limitation to the scope of the invention. Some suitable techniques are described above with reference to antibody labelling. Assays may involve immobilising antibody or peptide, as the case may be, on a suitable solid phase or support, such as latex
20 particles, magnetic or non-magnetic beads, a membrane, chip, plastic, metal, silicon or glass surface, or any other suitable material at the disposal of the skilled person. Detection may be qualitative or quantitative. One or more
25 appropriate controls may be included, in accordance with

standard practice.

As noted already, peptides, polypeptides, antibodies and nucleic acid in accordance with the present invention may be formulated into compositions, and are useful in pharmaceutical contexts. These compositions may include, in addition to one of the above substances, a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The precise nature of the carrier or other material may depend on the route of administration, e.g. oral, intravenous, cutaneous or subcutaneous, nasal, intramuscular, intraperitoneal routes.

Compositions for oral administration may be in tablet, capsule, powder or liquid form. A tablet may include a solid carrier such as gelatin or an adjuvant. Liquid pharmaceutical compositions generally include a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included.

For intravenous, cutaneous or subcutaneous injection, the

active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability. Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's Injection. Preservatives, stabilisers, buffers, antioxidants and/or other additives may be included, as required.

10 Branched peptides, such as MAP (Tam, J.P, 1988) may be used for the preparation of immunogens, either alone or linked to an appropriate carrier.

A linear peptide for use in raising an immune response may also be linked to an appropriate carrier. Various methods of coupling peptides to other molecules are known in the art, including disulphide forming reagents (where the peptide includes a cysteine - or a cysteine is added to the peptide for this purpose), thio-ether forming coupling agents and so on. Carriers include human serum albumin (HSA), tetanus toxoid, other rather large proteins that have reasonable half-lives under physiological conditions, and stable non-proteinaceous molecules such as polysaccharides and copolymers of amino acids.

An adjuvant may be included, such as alum, oil-in-water emulsions or Freund's Adjuvant (Complete or Incomplete). Cytokines may be used to potentiate immunogenicity of the peptide or polypeptide composition.

5

Mimotope sequences may be cloned into the context of the HCV envelope (E2) protein in order to use the natural folding environment for correct presentation of the epitope or epitopes to the immune system.

10

Naked DNA may be used for immunization (see e.g. Cohen, J, 1993), and one or more mimotope sequences may be cloned into suitable vectors (see e.g. Major et al., 1995). Naked DNA may be delivered using direct injection or by use of gene-guns (Yang et al., 1990) or any other suitable technique.

15

Whether it is a polypeptide, antibody, peptide, nucleic acid molecule, small molecule or other pharmaceutically useful compound according to the present invention that is to be given to an individual, administration may be in an immunogenic amount, that is sufficient to raise an immune (particularly antibody) response in the individual, or in a "prophylactically effective amount" or a "therapeutically effective amount" (as the case may be, although prophylaxis may be considered therapy). A prophylactic effect is

25

sufficient to potentiate the immune response of an individual to a subsequent challenge with HCV, E2HV polypeptide, or HVR1 peptide, or to a subsequent infection with HCV, preferably in the latter case (HCV infection) to sufficient to antagonise the infection, wholly or partially. Most preferably the effect is sufficient to prevent the individual from suffering one or more clinical symptoms as a result of subsequent HCV infection, and/or protect the individual from hepatitis C. A therapeutic effect is sufficient to potentiate the immune response of an individual to pre-existing HCV infection, preferably sufficient to antagonise the infection, wholly or partially. Most preferably the effect is sufficient to ameliorate one or more clinical symptoms, and/or cure the hepatitis C and/or reduce viral titre in the individual. The actual amount administered, and rate and time-course of administration, will depend on the nature and severity of what is being treated. Prescription of treatment, e.g. decisions on dosage etc, is within the responsibility of general practitioners and other medical doctors, and typically takes account of the disorder to be treated, the condition of the individual patient, the site of delivery, the method of administration and other factors known to practitioners. Examples of the techniques and protocols mentioned above can be found in Remington's Pharmaceutical Sciences, 16th edition, Osol, A. (ed), 1980.

Further aspects of the invention provide methods of treatment including administration of a peptide, mixture of peptides, antibody molecule or mixture of antibody molecules, as provided, pharmaceutical compositions including such a

5 peptide, mixture of peptides, antibody molecule or mixture of antibody molecules, and use of such a peptide, mixture of peptides, antibody molecule or mixture of antibody molecules, in the manufacture of a medicament for administration, for example in a method of making a medicament or pharmaceutical

10 composition including formulating the specific binding member with a pharmaceutically acceptable excipient.

A composition may be administered alone or in combination with other treatments, either simultaneously or sequentially

15 dependent upon the condition to be treated and the availability of alternative or additional treatments.

One aspect of the present invention provides use of a peptide as disclosed in the manufacture of a medicament for raising in

20 a mammal antibodies able to bind HCV HVR1 epitopes.

Another aspect provides a method of immunising a mammal against HCV infection, the method including administering a peptide or mixture of peptides to the mammal.

A still further aspect provides a method of (passively) immunising a mammal against HCV infection, the method including administering an antibody according to the invention to the mammal, or a mixture of antibodies.

5

Similarly, further aspects of the invention provide a method of treating a mammal with an HCV infection, the method including administering a peptide according to the invention, or a mixture of peptides, or an antibody, or a mixture of antibodies, to the mammal.

The antibodies may be anti-idiotypic antibodies.

Aspects and embodiments of the present invention will now be illustrated further and experimentally exemplified with reference to various figures. Further aspects and embodiments of the present invention will be apparent to those of ordinary skill in the art.

20 In the figures:

Figure 1(A) illustrates derivation of the consensus pattern of the 234 natural variants of the HCV HVR1 sequences used in this work. Non shaded residues within the box account alone for about 80% of the observed variability. Residues are

25

listed in decreasing order of observed frequency from top to bottom.

Figure 1(B) shows the composition in the initial HVR1 peptide library which was displayed on bacteriophage.

Figure 2 shows reactivity of phage pools yielded by the first round of affinity selection to antibodies present in the selecting sera. For each serum sample (01, 04R, 03, 02P, 02R, 03R and 0N) antibody recognition of the phage pools (pool 1, 4R 3, 2P, 2R, 3R and N), wild type phage (wt) and the unselected library (HVR1 lib) was measured. Average values (A_{405nm}) from two independent experiments have been determined.

Figure 3 shows distribution of HCV-specific phage selected from the HVR1 library as function of their frequency of reactivity with sera from infected patients. Binding is shown for phage enriched by one (top panel) or two (bottom panel) cycles of affinity selection to antibodies present in twenty human sera different from those used for the selections. For each serum, average values (A_{405nm}) from two independent experiments have been determined on the selected phage and on wild type phage. Values were considered statistically significant when differing more than $3\sigma_{max}$ ($p < 0.003$) from the

background signal observed for the wild type phage. Each histogram represents the number of phage (shown on the vertical axis) reacting with the indicated number of sera expressed as percentage over total number of tested samples (horizontal axis).

Figure 4 shows that the selected mimotopes are frequently recognized by antibodies present in human sera from HCV infected patients. Binding of the selected mimotopes to antibodies present in human sera was detected by ELISA on immobilised phage. Mimotopes' names are indicated at the top of each column. For each serum (indicated on the left of each row), average values (A_{405nm}) from two independent experiments have been determined. Results are expressed as the difference between the average value of the tested phagotope and that of wild type phage. Positive values are indicated in bold. Values were considered statistically significant when differing more than $3\sigma_{max}$ ($p < 0.003$) from the background signal observed for the wild type phage. The frequency of reactivity of each mimotope and that resulting from the sum of the reactivities observed with all four mimotopes are shown at the bottom of each panel.

Figure 4(A) shows reactivity of selected mimotopes with the panel of twenty HCV patients' sera used for the screening

step.

Figure 4(B) shows reactivity of selected mimotopes with an additional panel of sera from HCV-infected viremic patients.

5

Figure 4(C) shows reactivity with sera from non viremic patients that were scored positive for anti-HCV antibodies using commercially available kits.

10 Figure 5 shows correlation between the S-score and the frequency of reactivity of the selected mimotopes. The straight line represents the linear least square fit of the data. The correlation coefficient is 0.79.

15 Figure 6 shows that the selected mimotopes are antigenic mimics of a large number of naturally occurring HVR1. Antibodies from a pool of sera from HCV infected patients were immunopurified on MAPs reproducing the sequence of selected mimotopes (indicated at the top of the figure). Reactivity of
20 equal amounts of the immunopurified antibodies was measured by ELISA on a representative panel of HVR1 sequences synthesized as MAPs (indicated in the left column). Average values from two independent experiments were determined. Values were considered statistically significant when two criteria were
25 contemporarily fulfilled: (1) values were differing more than

$3\sigma_{\max}$ ($p < 0.003$) from the background signal observed on two unrelated peptides; (2) values were differing more than $3\sigma_{\max}$ ($p < 0.003$) from the average signal observed using ten sera from non infected individuals on each peptide representing a

5 natural HVR1. Grey boxes indicate signals differing from those observed on the unrelated MAPs between 0.15 and 0.5 OD (405nm); black boxes indicate values differing more than 0.5 OD (405nm). The level of cross-reactivity of each pool of immunopurified antibodies is indicated at the bottom of each

10 column.

Figure 7 shows correlation between mimotope sequence and cross-reactivity.

15 Figure 7(A) shows the sequences of the mimotopes used in the analysis.

Figure 7(B) shows correlation between the S-score of the mimotopes and the cross-reactivity of immunopurified human

20 antibodies with a panel of 43 natural HVR1 sequences. The straight line represents the linear least square fit of the data. The correlation coefficient is 0.86.

Figure 8 shows that the selected mimotopes are immunogenic

25 mimics of a large number of naturally occurring HVR1.

Reactivity of sera from mice immunised with single HVR1 mimotopes (Figure 8(A)) and mixtures of mimotopes (Figure 8(B)) in the form of MAP was assayed by ELISA on the panel of natural HVR1 sequences (indicated in the left column).

- 5 Immunizing mimotopes are shown in the first row. MIX1 includes mimotopes R9, F78, H1 and D6; MIX2 contains M122 and G31 peptides; MIX3 is composed of all six MAPs. Titres (defined as the dilution required to obtain half maximal signal in ELISA on the homologous peptide) are shown in the
- 10 second row. Sera were diluted 1:100. Average values from two independent experiments have been determined. Values were considered statistically significant when differing more than $3\sigma_{\max}$ ($p < 0.003$) from the background signal observed on two unrelated peptides. Grey boxes indicate signals differing
- 15 from those observed on the unrelated MAPs between 0.15 and 0.5 OD (405nm); black boxes indicate values differing more than 0.5 OD (405nm). The level of cross-reactivity of each serum is indicated at the bottom of each column.

- 20 Figure 9 illustrates plasmids employed in *in vivo* nucleic acid immunisation experiments described in Example 6.

EXAMPLE 1 - Design and construction of a specialised phage library mimicking the HVR1 variability

A multiple sequence alignment of 234 unique HVR1 sequences extracted from the sequence databases was made to characterise the variation in residue composition at each of the N-terminal 27 positions of the HCV E2 glycoprotein. A sequence pattern emerged from this analysis (Figure 1A) allowing the definition of a degenerate consensus sequence. A synthetic repertoire of HVR1 sequences was designed to contain such conserved constraints while reproducing the observed natural variability in the remaining positions.

A "consensus-profile" accounting for approximately 80% of the total sequence variability was derived by selecting the most frequent residues at each position. When similar amino acids were present at a given position, only one was chosen as representative of the variability, preferring those residues which could more effectively form interactions. For example, in position 5 both Ser and Thr are present in the natural repertoire, but only Thr was selected to design the library (Figure 1). In some cases, a residue not present in the consensus was included in the library to better mirror the overall variability. For example, Thr was included in position 3 to account for the presence of Ser, Thr, Asn in the natural repertoire of HVR1s.

The resulting final consensus profile (Figure 1B) has a

complexity of 9×10^7 very close to the upper practical limit (about 10^8) of current DNA cloning and transformation techniques. The amino acid most frequently observed in the natural repertoire was always included with the exception of position 1, (where Gln and Thr were selected although Glu is the most frequently observed amino acid). Eight positions (2, 6, 7, 16, 19, 20, 23 and 26) were kept constant given the high local sequence conservation throughout the 234 natural HVR1 variants. Noteworthy also is the total absence of negatively charged residues. With the exception of position 1, where Gln was chosen to represent the His, Glu, Asp, Gln, Asn group, no acidic residues were present within the 80% fraction. Qualitatively, the profile can be described as a generally more variable central region flanked by N-terminal and C-terminal tails containing conserved elements.

Construction of the library proceeded by cloning a degenerated synthetic oligonucleotide as a fusion to the 5' end of the gene coding for the major coat protein (pVIII) in a phagemid vector for M13 display (see Materials and Methods). About 2×10^8 independent transformants were obtained. To verify the quality and complexity of the library (HVR1 library), the inserts of fifty-six randomly chosen individual clones were sequenced. This analysis led to the following results:

- (1) all clones displayed different sequences;
 - (2) 63% of the clones contained full-length inserts while the remaining ones had small deletions;
 - (3) none of the sequenced clones encoded for peptides
- 5 corresponding to known HVR1 from viral isolates, searched on 15 March 1998.

From these data it was inferred that the library has a complexity close to the number of individual transformants.

10 *EXAMPLE 2 - Identification of HVR1 mimotopes frequently reacting with HCV patients' sera*

The more complex and diverse the repertoire of antibodies used
15 for the selection, the higher should be the probability to enrich phage recognised by many different antibodies against HVR1 epitopes. Sera from chronically infected, viremic patients appear to meet these requirements as these individuals have a rather long history of viral persistence,
20 during which a large number of HCV variants have been generated and have challenged the immune system, presumably leading to the accumulation of a highly heterogeneous population of anti-HVR1 antibodies.

25 Eight sera from chronic patients infected by viruses of five

different genotypes: 1a, 1b, 2a, 2b, 3a (Simmonds et al., 1993) were used to perform six affinity selections of the HVR1 library (Table 1). As control, a serum from a non infected individual was also used. Pools of phage obtained from all seven selections were amplified and tested for their reactivity to each of the selecting sera in ELISA. The results of this experiment showed a significant enrichment of phage recognised by the selector antibodies, as evidenced by the increase in reactivity with respect to the unselected library (Figure 2). In most cases, phage pools enriched by HCV sera reacted with more than one patient's serum. Peptides recognised by antibodies unrelated to HCV infection were also enriched from the library. In fact, the pool of phage selected with the control serum has a higher reactivity with this serum than the unselected library (Figure 2). However, patients' sera drove selection toward HCV-related mimotopes as no reactivity to phage pools enriched by HCV sera was detected using sera from healthy individuals (Figure 2 and data not shown).

20

To gain insight into the frequency of reactivity of the selected mimotopes with different patients' sera, forty individual clones from two pools (4R and 2R, Table 1) were randomly chosen and tested for their reactivity in ELISA with a panel of twenty sera from HCV infected patients different

25

from those used for the selection. An equivalent number of sera from non-infected healthy controls were used to assess the specificity for anti-HCV antibodies. Twenty-four clones turned out to be HCV-specific. Their distribution as a function of their frequency of reactivity with patients' sera is reported in Figure 3 (upper panel). Among them, phage reacting with more than one serum were identified; some of these were recognised by up to 55% of the tested sera.

- 10 To further improve the isolation of mimotopes reacting with many different anti-HVR1 antibodies, the enriched phage pools were subjected to a second round of affinity selection using patients' sera different from those used for the first round. In this way nine new pools were generated (Table 1) and
- 15 analysed by ELISA. As before, a general increase in reactivity with the selector antibodies was observed. In addition, all second round phage pools reacted more frequently than those selected in the first round with a panel of sera from HCV-infected patients different from those used for
- 20 either selection, reflecting a higher recognition frequency of the isolated peptides. This was confirmed by comparing the reactivity with HCV sera of clones randomly chosen among those eluted after one round of affinity selection (Figure 3, upper panel) and those obtained by re-selecting them with a second
- 25 different serum (Figure 3, lower panel). Not only the

frequency, but also the distribution of reactivity appeared to be significantly different after the second selection step. While recognition of phage from the first selection appears to be rather scattered, clones isolated through two rounds of selection show a bell-shaped distribution of their frequency of reactivity with an average value of 60% (Figure 3, lower panel), indicating that the whole phage population had indeed acquired more of the desired binding properties. It was decided to omit additional selection cycles to avoid introduction of a bias toward biologically favoured phage during amplification.

A total of one hundred and seventy one clones reacting exclusively with HCV sera were identified by screening all second-round pools. Their distribution as a function of the recognition frequency by HCV sera mirrored that of the subset displayed in Figure 3, lower panel, with the best clones reacting with 80% of the tested samples. More importantly, the profiles of reactivity of the selected mimotopes highlight another relevant feature. Despite their quantitative similar overall frequency of recognition by the HCV sera, different clones display a characteristic pattern of reactivity with the net result that few mimotopes can score for the presence of anti-HVR1 antibodies in all tested sera (Figure 4A).

Next, it was verified whether the observed high frequency of recognition by HCV sera was limited to the tested patients' population or whether it reflected an intrinsic property of the selected mimotopes. For this purpose another set of sera from infected patients was assayed by ELISA revealing that both the frequency of reactivity of each individual phage and the total coverage of the sera remained unaltered (Figure 4B).

HCV infected individuals who have resolved the infection most likely came in contact with a lower number of viral variants and presumably developed a narrower spectrum of variant-specific anti-HVR1 antibodies than chronically infected patients. This is supported by the finding that sera from the former population react with synthetic peptides reproducing the HVR1 of natural isolates much more rarely than those of chronically infected viremic patients (Scarselli et al., 1995). Therefore, non viremic sera could constitute a better and more stringent test for assaying the cross-reactivity of HVR1 mimotopes with different anti-HVR1 antibodies. Some of the selected mimotopes were thus tested against forty-one samples from HCV seropositive individuals who were repeatedly found negative for the presence of viral RNA in the blood. Again, the mimotopes reacted with many of these sera albeit at a lower frequency than that observed with sera from viremic patients (compare Figures 4(A), 4(B) and 4(C)). These data

provide an indication of the ability of the selected mimotopes to cross-react with a large number of different anti-HVR1 antibodies.

5 *EXAMPLE 3 - Determination of a relationship between the sequence of the selected HVR1 mimotopes and their frequency of reactivity with HCV sera.*

The inventors wished to verify whether the amino acid sequence
10 of the selected clones correlates with their frequency of reactivity. No obvious pattern arises from a visual comparison of the sequences so it was decided to analyse separately the sequence patterns of the least and most frequently reacting clones.

15 Defined as "weak" were the 24 clones that only reacted with less than 3 sera and defined as "strong" were the 27 reacting with more than 11 sera. The amino acid frequencies at each position of weak and strong clones are listed in the Materials
20 and Methods section below, and in Table II.

There is a clear trend for some positions to be occupied by different amino acids in the sets of weak and strong clones and this allowed us to heuristically define a position-based
25 scoring system described in Materials and Methods (see below).

The higher is the score of a clone (S-score) the more similar its sequence is to those of the strong clones and the more different from those of the weak ones. As shown in Figure 5, the S-score correlates reasonably well (correlation coefficient = 0.75) with the experimentally determined frequency of reactivity of each clone. It should be emphasised that the S-score was calculated using only the sequences of the "weak" and "strong" clones (51 out of 171), but it correlates well with the frequency of reactivity of all clones. Interestingly, a nearly identical result (correlation coefficient = 0.72) can be obtained using only 6 positions where the residue preference of the weak and strong mimotopes differ most (positions 3, 11, 18, 21, 22, 24).

EXAMPLE 4 - The HVR1 mimotopes antigenically mimic a large number of HVR1 variants from HCV isolates.

The inventors set to measure the cross-reactivity of human antibodies which recognise the mimotopes, with sequences representing naturally occurring HVR1.

For this purpose the mimotopes were used as immunoadsorbents to purify the specific antibodies from the bulk of anti-HVR1 present in infected patients' sera. Mimotopes R9, F78, M122, R6, B14, G31, H1 and D6 (Figure 7) were chosen for these experiments because they were among those which displayed the

highest frequency of reactivity with the HCV sera. Mimotope N5 which was recognised by a significantly lower percentage of HCV sera than the average "good" mimotopes (35% and 60-80%, respectively) was also used.

Although some lymphocyte cell lines have been shown to support limited replication of HCV (Shimizu et al., 1992), these systems are not suited for viral propagation and for a detailed study of the cross-reactivity of anti-HVR1 antibodies. Therefore, the cross-reactivity of the immunopurified antibodies on a panel of synthetic peptides reproducing natural HVR1 variants which approximately cover the observed sequence variability was determined.

To this end, a multi-dimensional cluster analysis (Casari et al., 1995) was performed on the same set of 234 aligned natural HVR1 sequences used for the construction of the library. Out of these, forty-three sequences nearly homogeneously distributed over the HVR1 "sequence space" were chosen (see Materials and Methods below) and synthesised as multiple antigenic peptides (MAP; Tam, J.P., 1988; Pessi et al., 1990). A pool of eight sera from infected patients collectively reacting with the entire panel of forty-three MAPs was used as a source of antibodies. The immunopurified antibodies displayed the same reactivity to the mimotope used

for the purification compared to the total serum. In contrast, no reactivity to a recombinant HCV core antigen or to the antigens included in a commercially available kit (see below in Materials and Methods) was retained after purification thus testifying to the efficiency and the specificity of the purification.

All immunopurified antibodies reacted with a significant number of natural HVR1 sequences with mimotope R9 yielding antibodies cross-reacting with 79% of natural HVR1 (Figure 6). As most immunopurified antibodies also displayed some non-overlapping reactivities to the natural sequences, an even higher level of overall cross-reactivity (88%) can be reached by adding up the individual contributions of antibodies purified from only three different mimotopes (R9, F78 and M122, Figure 6). From these data it was concluded that a limited set of HVR1 mimotopes can antigenically mimic a large number of natural HCV HVR1 variants.

Antibodies immunopurified by mimotopes with higher S-score, and consequently with a higher frequency of reactivity, also showed to be more cross-reactive. Eight mimotopes were used and, as shown in Figure 7B, the correlation between this sequence related score and the cross-reactivity of the corresponding antibodies is very good ($r = 0.86$; Figure 7B).

EXAMPLE 5 - The HVR1 mimotopes induce antibodies recognising many natural HVR1 variants.

A problem prior to the present work was the generation of immunogens able to induce antibodies cross-reacting with the largest number of HCV HVR1 natural variants. The immunogenic potential of some of the best HVR1 mimotopes (R9, F78, M122, G31, H1 and D6) was investigated by injecting them in mice both as whole purified phage and, outside of the original context in which they were selected, as MAPs.

MAPs turned out to be much more potent immunogens presumably due to the insufficient loading of HVR1 peptides on each phage as indicated by mass spectrometry analysis (less than 1% of the total pVIII content). Some variability in the efficiency of immunization was observed between the mimotopes as shown by the difference in titre, with F78 being able to induce antibody titres higher than 1/100,000 as measured by ELISA on the same peptide used for the immunisation (Figure 8A). Anti-HVR1 mimotope sera were then tested for their ability to recognise heterologous HVR1 variants by ELISA on the panel of forty-three MAPs reproducing HCV sequences from natural isolates. Most of these MAPs were recognised by the immune sera (Figure 8A), while no reactivity was observed on unrelated control peptides.

The cross-reactivities of the sera of mice immunised with mimotopes did not rank as that of human antibodies immunopurified with the same mimotopes. However, mimotope N5, which showed significantly lower levels of reactivity in both types of assays, revealed to be a much less efficient immunogen, leading to an anti-HVR1 response able to recognize only a minority of the natural HVR1 sequences (Figure 8A).

The extent of cross-reactivity of the immune sera generally reflects the immunogenicity of the individual MAPs as, in most cases, a higher titer corresponds to a higher level of cross-reactivity (Figure 8A). Nevertheless, titer alone cannot always explain the difference in cross-reactivity and in the pattern of reactivity displayed by the mimotope induced sera as clearly shown in the case of the anti-G31 serum which has a lower titer than the anti-F78, but reacts with a larger number of natural HVR1 peptides. Similarly, the anti-D6 serum displays the same level of cross-reactivity of the anti-R9 despite a three fold lower titer (Figure 8A).

The pattern of reactivity displayed by each antiserum is only partially overlapping with that of the others, and, in some cases, unique reactivities were observed. As a consequence of this feature of the induced sera, by adding up all the reactivities, almost all natural HVR1 peptides are recognized

(91%, Figure 8A). This observation is a significant improvement toward the goal of generating broadly reacting antibodies, provided one can obtain a similar increase in cross-reactivity a single immunization with a cocktail of mimotopes. Therefore, three groups of Balb/c mice were immunised with mixtures of mimotopes. Mixture 1 contained mimotopes R9, F78, H1 and D6; mixture 2 was composed of mimotopes M122, and G31, while mixture 3 comprised all six mimotopes. All three mixtures were immunogenic, and induced highly cross-reactive antisera (Figure 8B). Each of the three antisera displayed the same or an even higher cross-reactivity than that measured by adding up the reactivities of the antisera induced by each of the mimotopes included in the mixture (84% vs 84% for MIX1, 84% vs 81% for MIX2 and 95% vs 91% for MIX3, Figure 8B). The titers of these sera although high, were not better than those obtained with individual MAPs. It was therefore concluded that the ability of inducing highly cross-reacting response is not simply a consequence of the efficiency of the immunisation.

MATERIALS AND METHODS

Human sera

Human sera from HCV-infected patients and from healthy

individuals were characterised for the presence of antibodies to HCV by a second-generation HCV ELISA test system (Ortho-HCV ELISA, Ortho Diagnostic Systems, Bersee, Belgium) and by a first generation dot blot immunoassay (RIBA-HCV test, Chiron Co., Emeryville, CA). The presence of HCV RNA was detected by nested reverse transcription-PCR using conserved primers localised in the 5' non-coding region of the viral genome and total RNA extracted from 100 μ l of serum as previously described (Silini et al., 1995).

Construction of the HVR1 library

To back-translate the consensus profile described above with reference to Figure 1B into the corresponding nucleotide sequence, the *E. coli* codon usage table was employed selecting codons most frequent in highly expressed genes. To facilitate insertion of the library into the phagemid vector two additional constant sequences containing the recognition sites for the restriction enzymes PacI and NotI were added 5' and 3' to the 81bp segment, respectively giving a total of 116 bp. Absence of NotI and PacI restriction sites in the backtranslation of the consensus profile was verified by computer-assisted sequence analysis. For the chemical synthesis a codon-based "split-and-pool" method (Cormack et al., 1993) was applied in order to keep both library

composition and complexity at the desired level. The 116 bp oligonucleotides were amplified with primers complementary to the flanking constant sequences in a 9600 DNA Thermal Cycler (Perkin-Elmer Cetus, Foster City CA). The PCR product was
5 digested with PacI and NotI enzymes and gel-purified. The recovered DNA fragment was cloned between the PacI and NotI sites of the pel8PN phagemid vector (a derivative of pc89; Felici et al., 1991) downstream of the pelB secretion leader and upstream of the entire gene VIII coding sequence.

10 Recombinant phagemids were electroporated into DH10B competent cells. Since DH10B cells cannot be infected by filamentous phage and do not allow for blue/white selection, transformed cells were collected and plasmid DNA was prepared. This DNA was used to transform by electroporation XL1-blue competent
15 cells. Ampicillin resistant colonies were scraped from the plates and resuspended in LB/100 μ g ampicillin/ml and 10% (v/v) glycerol. A portion of this bacterial suspension was inoculated into six litres of LB medium containing 100 μ g ampicillin/ml at 0.05 O.D._{600nm} and grown with vigorous shaking
20 until 0.25 O.D._{600nm} was reached. The culture was then superinfected with M13K07 helper phage and grown for additional five hours to obtain the phage particles in the supernatant. The phage were precipitated twice with polyethylene glycol and purified by equilibrium centrifugation
25 in CsCl as described (Felici et al., 1991).

DNA-sequencing was performed as described (Bartoli et al., 1996) using an Applied Biosystem 373 DNA sequencer.

Library affinity selection

5 ELISA multiwell plates (Nunc Maxisorp, Roskilde, Denmark) were coated overnight at 4°C with 0.5 µg/ml of anti-human (Fc-specific) polyclonal Ab (Immunopure goat anti-human IgG Fc-specific; Pierce, Rockford, IL) in 50 mM NaHCO₃ pH 9.6. The
10 plates were washed with PBS/0.1% Tween 20 (washing buffer) and incubated for 1 hr at 37°C with 100 µl/well of blocking buffer (5% non fat dry milk, PBS/0.05% Tween 20). 1 µl of human serum diluted 1:100 in PBS /0.1% BSA was added to each well and incubated overnight at 4°C. After washing, 10¹² particles
15 of U.V. killed M13K07 diluted in PBS/0.1% Tween 20, 0.01% BSA, were then added to each well and incubated for 4 h at 4°C. After this pre-incubation, 10¹² particles/well of HVR1 library were added and incubated overnight at 4°C. Unbound phage were removed and several rounds of washing were
20 performed. Bound phage were eluted with 200 µl of elution buffer (0.1M HCl adjusted to pH 2.5 with glycine, 1 mg/ml BSA) and neutralised with 2M Tris-HCl pH 9. Eluted phage were titrated by infection of XL1-blue bacteria and the percentage of clones containing a productive insert was determined by
25 plating infected bacteria on X-gal/IPTG indicator plates

(Pelici et al., 1991). After amplification (see above) enriched phage were subjected to a second cycle of affinity selection following the same procedure.

5 *Sequence analysis of the mimotopes and definition of the S-score*

Out of a total of 193 selected clones, 171 showed no point mutation (with respect to the original library design) or deletions and were divided in three classes: 24 weak clones (reacting with less than 3 out of the 20 tested sera), 27 strong clones (reacting with at least 12 sera) and intermediate (the remaining clones).

15 For each amino acid at position i of a 27-mer amino acid sequence, we call $F_s(i, aa)$ and $F_w(i, aa)$ the observed frequency of the same amino acid in position i of the set of strong and weak clones, respectively.

20 The frequency values are shown in Table II.

$S\text{-score}(i)$ was then defined as the difference between the square roots of $F_s(i, aa)$ and $F_w(i, aa)$. The sum over the all 27-mer sequence of $S\text{-score}(i)$ is our sequence based S-score.

25 In practice:

$$S\text{-score} = \sum_i (\sqrt{F_s(i,aa)} - \sqrt{F_w(i,aa)})$$

where aa is the observed amino acid in position i of the sequence for which the S-score is calculated. The square root of the frequencies was used to amplify differences. For
5 clones where a point mutation or deletion had occurred, the corresponding position was omitted in the score calculation.

Selection of a representative set of natural HVR1 sequences

10 The NS1 HVR1 sequence from the HCV BK strain (residues 384-411) was used to search various databases (on 13 December 1995), both protein (SwissProt, PIR and Genpept, the latter representing assigned open reading frames from Genbank and EMBL) and nucleotide sequence (EMBL, Genbank and EST).
15 Duplicated and incomplete sequences were removed from the list of matching sequences to obtain a unique set of 234 natural HVR1 sequences.

Principle component analysis was used to select 40 sequences homogeneously distributed over the set. First, all pairwise
20 distances between the 234 sequences were calculated using the first six eigenvalues calculated using Sequencespace (Casari et al., 1995). Sequences with the smallest distances to neighbouring sequences were eliminated in a stepwise procedure until only 40 sequences remained. Projections into two

dimensions along all possible pairs of Eigenvectors showed that the set of 40 sequences did not cluster and were homogeneously distributed.

5 Accession numbers and sequences are:

- 1 Genbank:D12967 QTRTVGGQMCHGVRGLTSLFSGSARN bp 46- bp 126
- 2 PIR:PC1193 STHVTGALQGRAAYGITSFLSHGPSQK aa 16- aa 42
- 3 Genbank:D00574 HTRVTGGVQGHVSTLTSLPRPGASQK bp1240- bp1320
- 4 Genbank:L19383 ETHTSGGSVARAAFGLTSLFSPGAKQN bp 46- bp 126
- 5 Genbank:M62381 ETHVTGGSAGRTTAGLVGLLTPGAKQN bp1426- bp1506
- 6 Genbank:U24616 ATYTTGGSAAKTAHRLASFPTVGPQKD bp 22- bp 102
- 7 PIR:C48776 DTHVVGATERTAYS LTGLFTAGPKQN aa 13- aa 39
- 8 Genbank:U24607 GTTCQGGVYARGAGGIASLFSVGANQK bp 22- bp 102
- 9 PIR:D48766 RTLSFGGLPGHTTHGFASLSAPGAKQN aa 13- aa 39
- 10 Genbank:X60573 RTILMAGRQAEVTQSFPGLFSLAPSQK bp 46- bp 126
- 11 Genbank:D43650 NTHAMGGVVARSAIRITSFLSPGAAQN bp 1- bp 81
- 12 PIR:PQ0835 STRITGGSMARDVYRFTGFFARGPSQN aa 6- aa 32
- 13*Genbank:S73387 GTHTIGGSQAQQANRFVSMFSRGPQK aa 190- aa 216
- 14 Genbank:D10934 NTYVTGGAAARGASGITSFLFSRGPQK bp1491- bp1571
- 15 Genbank:D31972 NTYASGGAVGHQTASFVRL LAPGPQN bp1409- bp1489
- 16 Genbank:U14231 ETHTTGGEAARTTLGIASLFTSGANQK bp 103- bp 183
- 17 Genbank:U24602 ETHTTGGSAAATFGIANFFTPGAKQN bp 22- bp 102
- 25 18 Genbank:L19380 EYTTSGGSAAHTSGVSVFFSPGAKQN bp 46- bp 126
- 19 Genbank:M74888 GTTRVGGAAARTTSSFASLLTHGPSQN bp1147- bp1227
- 20 Genbank:L12354 NHTVTGAAAASRSTAGLTSLFSIGRSQK bp1468- bp1548
- 21 Genbank:X79672 NTRVTGGVQSRTTGT FVGLFTPGPSQR bp 1- bp 81

22 PIR:A48776 NTHVSGGRVGHHTTSLTSFPTGPGQK aa 13- aa 39

23 Genbank:D12952 STRVSGGQGGRAAHSLSLFTLGASQN bp 46- bp 126

24 Genbank:D16566 STRITAQAEGRGASTLSLFTSGASQK bp 8- bp 88

25 Genbank:M84754 STIVSGGTVARHTHSLASLFTQASQK bp1491- bp1571

5 26 Genbank:D14853 ETRVTGGAAGHTAFGFASFLAPGAKQK bp1491- bp1571

27 Genbank:S24080 NTYVTGGSAGRAVAGFAGLLQPGAKQN bp 46- bp 126

28 Genbank:S35631 ETHSVGGSAHHTSRFTSLFSPGPGQN bp 580- bp 660

29 Genbank:S62395 ETHVTGGSAASTSTLTKLPMGASQN bp 43- bp 123

10 30 Genbank:S70291 QTRTVGGANARNTYGLTTLFTTGPKQN bp 1- bp 81

31 Genbank:D88472 GTTTVGSASVSTTYRFAGMFSQGAQQN bp1485- bp1565

32 Genbank:D10687 NHTVVGTEGFATQRLTSLFALGPSQK bp1180- bp1260

33 Genbank:D43651 NTHVTGGVARNAYRITIFLNPQPAQN bp 39- bp 119

34 Genbank:D14305 HTYTTGGTASRHTQAFAGLFDIGPQK bp1427- bp1507

15 35 Genbank:X60590 KTHVTGMVAGKNAHTLSSIFTSGPSQN bp 46- bp 126

36 Genbank:D30613 GTHVTGKVAYTTQGFTSFFSRGPSQK bp1491- bp1571

37 Genbank:X53131 ETYTSGGNAGHTMTGIVRFFAPGPKQN bp 802- bp 882

38 Genbank:U24619 STYSMGGAHAHNARGLTSLFSSGASQR bp 22- bp 102

39 Genbank:M62382 ETHVTGGSAGRSVLGIASFLTRGPKQN bp1426- bp1506

20 40 Genbank:D88474 ETYIIIGAATGRTTAGLTSLSFGSGSQN bp1488- bp1568

*Sequence 13 corresponds to the translated amino acid sequence (aa190-aa216) reported in the CDS feature of Genbank entry S73387.

25

Three additional sequences were also synthesized as MAPS: Two sequences are derived from the pedigreed HCV inoculum H77 (Figure 2 of Farci et al., 1994):

41 (H77-1) ETHVTGGNAGRTTAGLVGLLTPGAKQN bp 1- bp 81

42 (H79) ETHVTGGSAGHTAAGIASFFAPGPKQN bp 1- bp 81

5 and one from the major isolate of a patient whose immunoreaction has been characterized (Scarselli et al., 1995):

43 Genbank:X79669 NTRVTGGVQSHTTRGFVGMFSLGPSQR bp 1- bp 81

10

Phage preparation and ELISA

Phage supernatants were prepared from XL-1 blue infected cells as previously described (Folgori et al. 1994). ELISA were performed according to Dente et al., (1994) using 25 μ l of phage supernatant/well. Sera were diluted 1:100 if not otherwise specified and revealed by addition of species-specific anti-IgG (Fc-specific) alkaline phosphatase-conjugated secondary antibodies (Sigma A-9544; dilution 1:5000 in ELISA blocking buffer). Results were recorded as differences between O.D._{405 nm} and O.D._{620 nm} by an automated ELISA reader (Labsystems Multiskan Bichromatic, Helsinki, Finland).

ELISA with phage pools were performed in the same way by using equivalent amounts (10^{10} ampicillin transducing units) of amplified phage after CsCl purification (see above).

100 μ l of MAPs representing natural HVR1 sequences were used to coat ELISA plates (Nunc Maxisorp, Roskilde, Denmark) at a final concentration of 10 μ g/ml in coating buffer (50mM NaHCO₃, pH 9.6). After blocking of free binding sites, 100 μ l/well of sera or affinity-purified antibodies were added. Mouse and rabbit sera were tested at final 1:100 dilution in blocking buffer; affinity purified antibodies were tested at final concentration of 150 ng/ml. Plates were incubated overnight at 4°C. After washing, 100 μ l/well of alkaline phosphatase conjugated secondary antibodies (goat anti-mouse IgG Sigma A-7434 diluted 1:2000; goat anti rabbit IgG Sigma A-8025 diluted 1:5000; goat anti human IgG Sigma A-9544 diluted 1:5000) were added and incubated one hour at room temperature. Plates were washed and alkaline phosphatase revealed as described above.

Affinity purification of antibodies from human sera

Multiple antigenic peptides reproducing the sequence of different mimotopes were used since they showed the same binding profile with HCV sera in ELISA as the phage, but proved to be more efficient in the affinity selection of the antibodies. Activated CH Sepharose 4B column (Pharmacia Biotech 17-0490-01) was coupled with the MAP of interest at the ratio of 1g of dried Sepharose/1mg of MAP in coupling buffer (0.1 M NaHCO₃, pH8/0.5M NaCl). Coupling was followed by

blocking of free amino-groups with 0.1M Tris-HCl pH8. Sample was loaded as a pool of eight HCV sera diluted 1:5 in coupling buffer. After adsorption at room temperature and extensive washing with PBS, bound antibodies were eluted with 0.1M glycine-HCl pH 2.7 supplemented with BSA at final concentration of 10µg/ml and immediately neutralised by 2M Tris-HCl pH9.4. The concentration of eluted antibodies was determined by ELISA using as standard human IgG (Sigma I-2511). Affinity-purified antibodies were checked for their reactivity in ELISA with the mimotope used for the purification (both in the form of MAP and phage) and, as control, with HCV-unrelated MAPs. The specificity of the purification was further confirmed by testing the eluted antibodies by ELISA on recombinant bacterially expressed HCV core protein (Prezzi et al., 1996) and by the second-generation HCV ELISA test (Ortho Diagnostic Systems, Bersee, Belgium). The total amounts of immunoglobulins recovered in each affinity purification from a standard amount of 1 ml of serum pool were comparable, ranging from 0.8 to 1.5 µg. For ELISA on the test MAPs the concentration was adjusted in every case to 150 ng/ml.

Animal immunisations

Immunising phage were prepared from XL1-blue infected cells

and CsCl purified as previously described (Felici et al., 1991). Three to five weeks old female BALB/C mice (Charles River, Como, Italy) were immunised by intraperitoneal injection of 100 μ l of antigen solution at day 0, 21 and 42 and bled at day 52 (third bleed) and day 148 (fourth bleed). Phage were injected as 0.9% NaCl suspensions at a concentration of about 0.3 mg/ml (2.5×10^{13} phage particles/ml) without added adjuvant.

10 For peptide immunisations, MAPs were dissolved in PBS at a final total concentration of 400 μ g/ml and injected as a 1:2 dilution in either Complete Freund's Adjuvant (first injection) or Incomplete Freund's Adjuvant (booster injections). Four to seven weeks old female Balb/c mice (Charles River, Como, Italy) were immunised by i.p. injection 15 of 100 μ l of antigen solution at weeks 0, 3 and 6 and bled at days 0 (pre-bleed) and 10 days after each additional injection. When more than one peptide were used for the immunization, equal amounts of each mimotope were mixed, and 20 100 μ l of a 400 μ g/ml solution was used.

EXAMPLE 6 - Immunogenic properties of peptides and E2 recombinant proteins. DNA immunisation in vivo.

25 Immunogenic properties of some of the selected HVR1 mimotopes

were explored either alone or as N-terminal fusion to the ectodomain of the E2 protein

The hcv E2 peptide is generally identified by the peptide spanning from amino acid 384 to amino acid 809 of the HCV polyprotein. The HVR1 region is generally identified as amino acid 384 to 410. In the following examples Δ E2 identifies peptides corresponding to aa411 to aa683 of the HCV polyprotein.

Construction of recombinant plasmids

Three types of plasmids were produced and their structure is reported in Figure 9:

- (i) p Δ E2 - directing the synthesis of an E2 protein fragment (HCV strain N, Nishihara et al.; Gene; 1993; 129 pp 207-214; from aa411 to aa683 of the HCV polyprotein) carrying a deletion of both the HVR1 and the C-terminal hydrophobic region;
- (ii) a second plasmid pF78 expressing one of the HVR1 mimotopes;
- (iii) a set of 11 constructs (pMimoE2) in which DNA sequences encoding for the eleven different HVR1 mimotopes were fused at the 5' end of the Δ E2 coding sequence in the plasmid p Δ E2.

All recombinants were cloned in frame downstream of the tissue plasminogen activator (TPA) signal sequence to enforce secretion of the antigen.

5 Δ E2 gene (therefore coding for the peptides spanning from aa 411 to aa 683) was cloned using as PCR template an E2 N strain containing vector (Nishihara et al.; Gene; 1993; 129 pp 207-214). A PCR fragment was obtained using synthetic oligonucleotide primers

10 (oligo fwd = GCGAGATCTTAATTAACGATATCCAGCTTATAAAC;
oligo rev = TCCGATCCTTAGTGGTGGTGGTGGTGGTGCGLAG).

By the use of these primers the resulting PCR product comprises, besides the Δ E2 gene, BglII, PacI and EcoRV
15 restriction sites at the 5' end, and a sequence coding for six histidine residues (His tag), and a TAA termination codon followed by BamHI restriction site at the 3' end. This PCR product is then digested with BglII and BamHI and ligated at the BglII site of V1JnsTPA vector (J.J. Donnelly et al. The
20 Journal of Infect. Diseases; 1996; 713; pp314-320) in frame with TPA leader sequence to obtain the plasmid V1JnsTPA- Δ E2 (designated p Δ E2 in Figure 9).

HVR1 mimotope sequences were subcloned at the 5' end of Δ E2

gene in pΔE2. HVR1 fragments were PCR-amplified directly from selected phage supernatant. The 5' primer contained PacI restriction site and was complementary to a 5' sequence (GGCGGCCGTTTAATTAAC) which is a constant part of HVR1 mimotope sequences; the 3' primers were complementary to the last 15 nucleotides and were different according to the mimotope sequence cloned. PCR-amplified fragments were PacI digested and ligated into pΔE2 plasmid. A total number of 11 pMimOE2 (Figure 9) plasmids were generated.

Furthermore a pF78 (Figure 9) plasmid was constructed by PCR amplification of F78 sequence

(oligo fwd = GCGAGATCTTAATTAACCAGACCATACCACC; oligo rev = TCCGGATCCTTACTGGTGGTGGTGGTGGTGGTCTCTGTTTCGCGCC) and cloning at the BglII site of V1JnsTPA vector.

Large-scale DNA preparations were performed using Qiagen 2500-Tip columns, following manufacturer's instructions (Qiagen, Hilden, Germany).

20 Characterisation of mimotope/E2 recombinant proteins

The ability of pF78, pAE2 and pMimoE2 plasmids to drive the expression of recombinant proteins in a mammalian system was assessed by transient transfection of 293 cells. pAE2 and

pMimoE2 transfected cells showed a strong and specific staining when probed with an anti-E2 monoclonal antibody (mAb-185) recognising an epitope located downstream of the HVR1. Also mF78 expression was demonstrated by immunocytochemistry of transfected 293 cells using a mice antiserum obtained by immunisation with a MAP reproducing the amino acid sequence of mimotope F78. These data were confirmed by ELISA on whole cell extracts from transfected cells. Significant amounts of all recombinant proteins were also secreted in the medium as measured by ELISA on cell culture supernatants from transfected cells.

Both intracellular and secreted proteins were heterogeneously glycosylated as suggested by their appearance as a cluster of slow migrating bands in SDS PAGE. The higher molecular weight displayed by the extracellular protein fraction is indicative of a different extent of glycosylation and confirms that the protein is actively secreted and not simply released by lysed cells. In both cases, endoglycosydase treatment leads to an increase of the migration rate to the one expected from the amino acid composition.

All recombinant mimotope/E2 fusion proteins as well as the AE2 mutant were efficiently recognised by two different conformation-sensitive monoclonal antibodies. Furthermore, no

cysteine-bridged multimeric aggregate was visible by Western blot on non reducing SDS PAGE of either the cellular or the secreted fraction from each clone. Similar results were obtained by transfecting mouse rhabdomyosarcoma cells thereby providing indication that efficient expression will be achieved upon *in vivo* transfection of mouse muscle cells.

Plasmid DNA immunisation

Four weeks old female Balb/c mice (Charles River, Como, Italy) were used for immunisations. Fully anaesthetised mice received from 100 μ g of plasmid DNA dissolved in 100 μ l of saline buffer (PBS). Fifty microliters of DNA were injected bilaterally into quadriceps muscle via insulin syringe (B-D, U-100 28G1/2 microfine needle). Mice were given three or four injections at 3-weeks intervals and were bled two weeks after each injection. Sera were analysed for antibody titre and cross-reactivity.

Serology of α AE2 and α HVR1 antibodies

ELISA 96 well plates (Immunoplate Maxisorp; Nunc, Roskilde, Denmark) were coated with 1 μ g/well GNA (Sigma L8275) in 50 mM NaHCO_3 at pH 9.6 and incubated overnight at 4°C. Plates were

washed (PBS/0.1% Tween 20) and incubated 1 hr at 37°C with 250 µl/well of blocking buffer (2% BSA, 1X PBS, 0.1% Tween 20).

F78E2 or ΔE2 proteins were produced by transient transfection in 293 cells. 10X concentrated supernatant were used as

5 target antigen in ELISA. Saturating amount of each protein/well were incubated in blocking buffer 3 hrs at RT on GNA-coated plates. Serial dilutions of immune sera (from 1:100 to 1:72900) were pre-incubated for 2 hrs at RT with 1 µl/well of 10X supernatant from mock transfected 293 cells in
10 blocking buffer. Sera incubation was performed o/n at 4°C.

After 1 hr at RT of IIAb incubation (α-mouse IgG Fc-specific AP conjugated, SIGMA 7434, diluted 1:2000 in blocking buffer), plates were developed for 30 minutes at 37°C.

15 Anti HVR1 mimotope antibodies were titrated (dilutions of sera from 1:100 to 1:72900) by ELISA assay using for each serum the homologous peptide sequence in the form of MAP.

In all cases sera titre was defined as the highest serum
20 dilution that resulted in an absorbance value of 0.3 O.D. (almost 6 times the background value).

Cross-reactivity assay

Sera were assayed for their cross-reactivity to different HVR1 natural variants using a set of 43 representative MAPS as described in Materials and Methods.

5 *Intramuscular injection of mimotope encoding constructs induces a strong humoral response*

Plasmids pAE2 and pF78E2 were used to set up the optimal conditions for induction of humoral response. Induction of antibodies against epitopes located outside of the HVR1 was monitored by ELISA using the AE2 protein expressed by transiently transfected 293 cells. Balb/C and C57black mice were immunised to test the immunogenicity of the mimotope encoding constructs in different genetic backgrounds. Both 10 the number of injections (from one to four) and the amount of injected DNA directly correlated with the magnitude of antibody response. The highest antibody titres against the AE2 protein were obtained after three injections at three weeks-intervals using fifty or one hundred micrograms of pAE2 15 DNA per mouse. Further injections did not improve titres. A similar kinetic of induction of antibodies against the AE2 protein was observed following mice immunisation with plasmid pF78E2. Induction of anti-HVR1 antibodies in this latter group of animals was tested by ELISA on MAPF78. No

significant difference was observed between the two strains of mice under investigation as far as the optimal conditions of immunisation are concerned, but C57black mice showed on average better responses.

5

Antisera from mice immunised with the construct expressing only the F78 HVR1 mimotope (pF78) also induced a specific response, but the titres were much lower than those obtained by using the related pF78E2 construct. Several factors such as the level of expression, the folding of the recombinant products or the presence of stronger T helper epitopes might be responsible for the higher response observed with the fusion constructs as compared to the F78 mimotope alone.

10

15

Anti-mimotope sera cross-react with different natural HVR1 variants

The ability of mimotope/E2 fusions to elicit a cross-reactive response by DNA-based immunisation, was evaluated using a panel of forty-three synthetic peptides reproducing the HVR1 sequences of natural isolates as coated antigens in ELISA (see Materials and methods).

20

25

In Table III are reported the average titres obtained by immunisation of Balb/c mice (upper panel) and C57Black mice

(lower panel) using different individual plasmids or mixtures of plasmids. Crossreactivity is reported as number of peptides scored as positive of the 43 tested.

5 pB14E2 and pB24E2 plasmids did not induce a cross-reactive immune response, in spite of the presence of significant levels of antibodies specific for a peptide displaying the homologous mimotope sequence in the relative immune sera (Table III). All the other constructs gave rise to anti-sera
10 cross-reacting against some of the natural HVR1 sequences, with the anti-F78 sera being able to recognise up to 28% of the tested peptides (Table III).

The extent of cross-reactivity of the immune sera generally
15 reflected the immunogenicity of the individual plasmids as, in most cases, a higher titre corresponded to a higher level of cross-reactivity (Table III). Nevertheless, titre alone cannot always explain the differences in cross-reactivity, as shown with sera from mice immunised with plasmid pR6E2 which
20 induced lower titres than the pD6E2, pH1E2 and pM63E2 constructs, but reacted with a larger number of natural HVR1 peptides. Similarly, sera from mice immunised with the pF7E2, pM122E2 and pR9E2 showed a cross-reactivity two fold higher than that observed with the pG31E2 immune sera, despite
25 similar titres (Table III).

In C57Black mice injection of the pF78E2 chimaeric gene led to the development of a stronger response with a consequently higher cross-reactivity as compared to Balb/C mice (49% vs 28%).

5

Immunisation with mixtures of plasmids improves the cross-reactivity of the response

10 Three groups of Balb/C mice were immunised with mixtures of plasmids encoding for mimotope/E2 chimaeras, each mouse receiving a total amount of 100µg DNA/injection.

15 Mixture A contained the plasmids encoding for D6, F78, G31, H1, M122 and R6 fusions to E2. Mixture B also included the other three constructs that induced cross-reactive antibodies: pE19E2, pM63E2 and pR9E2, while Mixture C comprised all eleven plasmids. (Mixtures of peptides, and nucleic acid encoding peptides, according to each of Mixture A, Mixture B and Mixture C represent further aspects of the present invention.)

20

All three mixtures were immunogenic, and induced highly cross-reactive antisera (Table III). Antibodies from animals immunised with Mixture A did not show higher cross-reactivity as compared to those obtained by injecting individual plasmids 25 included in the cocktails. However, it must be emphasised

that in the former case titres were about fifty fold lower, suggesting that Mixture A has the potential to induce a more widely cross-reacting response provided efficiency of the immunisation is increased. The results obtained with Mixture B lent further support to this hypothesis. Mice receiving the second mixture of plasmids showed a net increase in cross-reactivity in that they developed anti-sera able to recognise about 50% of the tested natural HVR1 sequences. Also in this case the average titres were one order of magnitude lower than those displayed by the most cross-reacting sera from animals immunised with individual plasmids (Table III).

Intramuscular delivery of the most complex mixture including all plasmids encoding for the mimotope/E2 chimaeras did not further improve the breath of reactivity of the resulting immune sera. This result is consistent with the observed lack of cross-reactivity displayed by the animals immunised with the two additional constructs present in this cocktail (pB14E2 and pB24E2).

Similar data were obtained by immunising C57black mice.

REFERENCES

- Alter, H.J. (1995) Blood 85, 1681-1695.
Bartoli, F., et al.(1996) BioTechniques 20 554-558.

- Bukh, J., (1995) Seminars in Liver Disease 15, 41-63.
- Casari, G., et al. (1995) Nature Structural Biology. 2, 171-178.
- Choo, Q.L., et al. (1989) Science 244, 359-362.
- 5 Choo, Q.L., et al. (1994) Proc. Natl. Acad. Sci. USA 91, 1294-1298.
- Cohen, J, (1993) Science 259: 1691-1692.
- Cormack, B.P. and Struhl, K. (1993). Science 262 244-248.
- Cortese, R., et al. (1994) Tibtech 12, 262-266.
- 10 Cortese, R., et al. (1996) Current Opinions in Biotechnology 7, 616-621.
- Dente, L., et al. (1994) Gene 148, 7-13.
- Farci, P., et al. (1992) Science 258 135-140.
- Farci, P., et al. (1994) Proc. Natl. Acad. Sci. USA 91, 7792-7796.
- 15 Farci, P., et al. (1996) Proc. Natl. Acad. Sci. USA 96, 15394-15399.
- Felici, F., et al. (1991) J. Mol. Biol. 222, 301-310.
- Folgori, A., et al. (1994) EMBO J. 13, 2236-2243.
- 20 Fried, M.W. and Hoofnagle, J.H. (1995) Semin. Liver Dis. 15, 82-91.
- Kato, N., et al. (1993) J. Virol. 67, 3923-3930.
- Kojima, M., et al. (1994) Virology 204, 665-672.
- Kurosaki, M., et al. (1994) Virology 205, 161-169.
- 25 Major, M.E., et al. (1995) J. Virol. 69, 5798-5805.

- Martell, M., et al. (1992) J. Virol. 66, 3225-3229.
- Martell, M., et al. (1994) J. Virol. 68, 3425-3436.
- Mast, E.E. and Alter, M.J. (1993) Semi. Virol. 4, 273-283.
- Mecchia, M., et al. (1996). J. Immunol., 157, 3727-3736.
- 5 Meola, A., et al. (1995). J. Immunol. 154, 3162-3172.
- Pessi, A., et al. (1990). J. Chem. Soc, Chemical
Communications, 1, 8-9.
- Prezzi, C., et al. (1996). J. Immunol. 156, 4504-4513.
- Scarselli, E., et al. (1995) J. Virol. 69, 4407-4412.
- 10 Shimizu, Y.K., et al. (1992) Proc. Natl. Acad. Sci. USA 89,
5477-5481.
- Shimizu, Y.K., et al. (1994) J. Virol. 65, 1494-1500.
- Shimizu, Y.K., et al. (1997). J. Virol. 71, 5769-5773.
- Silini, E., et al. (1995) Hepatology 21, 285-290.
- 15 Simmonds, P., et al. (1993). J. Gen. Vir. 74, 2391-2399.
- Tam, J.P. (1988) Proc. Natl. Acad. Sci. USA 85:5409-5413.
- van Doorn, L., et al. (1995) J. Virol. 69, 773-778.
- Weiner, A.J., et al. (1991). Virology 180, 842-848.
- Weiner, A.J., et al. (1992). Proc.Natl.Acad. Sci.USA 89 3468-
20 3472.
- Weiner, A., et al. (1995). Proc. Natl. Acad. Sci. USA 92,
2755-2759.
- Winter, G. and Milstein, C. (1991) Nature 349, 293-299.
- Yang, N.S., et al. (1990). Proc. Natl. Acad. Sci. USA 87: 9568-
25 9572.

TABLE I - Scheme of the selections.

First and second round of HVR1 library enrichment with sera from HCV infected patients are indicated at the top of the table. Names of the sera and the genotype of the corresponding infecting virus (in brackets) are shown in the left column. In the right column are indicated the names of the resulting phage pools.

TABLE II - Amino acid frequencies observed in the set of "strong" and "weak" crossreactive mimotopes.

i indicates amino acid position (1 to 27); aa indicates amino acids in standard one letter code; $F_s(i,aa)$ is the frequency in position i of the amino acid aa in the "strong" mimotopes; $F_w(i,aa)$ is the frequency in position i of the amino acid aa in the "weak" mimotopes.

Table I

Ist selection		IInd selection	
serum/genotype	phage pool	serum/genotype	phage pool
$\sigma 4R$ (1b)	4R	$\sigma 2$ (1b)	B
$\sigma 3R$ (3a)	3R	$\sigma 1$ (1a)	D
$\sigma 3$ (2a)	3	$\sigma 2$ (1b)	E
$\sigma 2R$ (3a)	2R	$\sigma 3$ (2a)	R
$\sigma 1$ (1a)	1	$\sigma 4$ (2a)	F
		$\sigma 2$ (1b)	H
$\sigma 2P$ (2b)	2P	$\sigma 2$ (1b)	G
		$\sigma 1$ (1a)	L
		$\sigma 4$ (2a)	M
σN	N		

Table II

i	aa	Fs (i,aa)	Fw (i,aa)
1	Q	0.70	0.64
	T	0.30	0.36
2	T	1.00	1.00
3	H	0.52	0.28
	T	0.48	0.12
	R	0.00	0.60
4	T	0.70	0.52
	V	0.30	0.48
5	V	0.56	0.36
	T	0.44	0.64
6	G	1.00	1.00
7	G	1.00	1.00
8	Q	0.41	0.24
	S	0.30	0.56
	V	0.29	0.20
9	A	0.48	0.28
	Q	0.37	0.40
	V	0.15	0.32
10	S	0.44	0.64
	G	0.37	0.32
	A	0.19	0.04
11	H	0.89	0.40
	R	0.18	0.60
12	Q	0.52	0.44
	A	0.26	0.20
	T	0.22	0.36
13	A	0.37	0.28
	T	0.33	0.52
	V	0.30	0.20
14	S	0.48	0.32
	H	0.41	0.32
	R	0.11	0.36

i	aa	Fs (i,aa)	Fw (i,aa)
15	S	0.52	0.32
	G	0.41	0.24
	R	0.07	0.44
16	L	1.00	1.00
17	T	0.78	0.52
	V	0.22	0.48
18	S	0.48	0.24
	G	0.41	0.36
	R	0.07	0.40
19	L	1.00	1.00
20	F	1.00	1.00
21	S	1.00	0.20
	R	0.00	0.80
22	P	0.89	0.32
	L	0.07	0.28
	Q	0.04	0.32
	S	0.00	0.08
23	G	1.00	1.00
24	A	0.41	0.04
	S	0.37	0.20
	P	0.22	0.76
25	K	0.41	0.32
	S	0.41	0.36
	Q	0.18	0.32
26	Q	1.00	1.00
27	N	0.67	0.52
	K	0.33	0.48

Table III

plasmid	titre	n. positive peptides
pB14E2	270	0
pB24E2	189	0
pD6E2	4222	3
pE19E2	990	2
pF78E2	31812	12
pG31E2	31251	5
pH1E2	2977	1
pM63E2	3888	2
pM122E2	41360	10
pR6E2	1923	6
pR9E2	21092	11
mF78	110	2
MIX	684	11
MIX	1224	19
MIX	610	18

plasmid	titre	n. positive peptides
pF78E2	41547	21
MIX	20381	24

CLAIMS:

1. A library of at least 10^5 different peptides each with an amino acid sequence according to the following formula

5 ("Formula I"):

```

Q T H V T G G S A A R T T S G L T S L F S P G A S Q N
T   T T V       V Q G H A A H S   V G       R L   P K   K
      R           Q V S   Q V R R       R           S   S Q
                                     Q

```

2. A library according to claim 1 including at least 10^6 different peptides each with an amino acid sequence according to said formula.

3. A library according to claim 2 including at least 10^7 different peptides each with an amino acid sequence according to said formula.

4. A library according to claim 1 wherein the peptides each have an amino acid sequence of the following formula ("Formula III"):

Q T H T V G G Q A S H Q A S S L T S L F S P G A K Q N
T T V T S Q G A T H G V G S S K
V V A T V R R P Q

5 5. A library according to claim 4 with at least 10^6
different peptides with an amino acid sequence according to
Formula III.

40 6. A library according to any of claims 1 to 5 displayed on
the surface of bacteriophage particles.

45 7. A method of obtaining one or more peptides containing an
epitope immunologically cross-reactive with an epitope in the
HVR1 of an HCV strain, the method including bringing into
contact a library of peptides according to any of claims 1 to
5 and an antibody molecule able to bind said HVR1 of an HCV
strain, and selecting one or more peptides of the library able
to bind said antibody molecule.

20 8. A method according to claim 7 wherein the peptide or
peptides selected contain an epitope immunologically cross-
reactive with the HVR1 of a plurality of strains of HCV.

25 9. A method according to claim 8 including bringing into
contact a library of peptides according to any of claims 1 to

5 and a plurality of antibody molecules collectively able to bind the HVR1 of a plurality of strains of HCV.

10. A method according to claim 9 wherein said plurality of
5 antibody molecules is derived from sera of individuals infected with HCV.

11. A method according to any of claims 7 to 10 wherein said
library is displayed on the surface of bacteriophage
10 particles, each particle containing nucleic acid encoding the peptide displayed on its surface.

12. A method according to claim 11 wherein nucleic acid is
taken from a bacteriophage particle displaying a said selected
15 peptide.

13. A method according to claim 12 including producing a
peptide by expression from nucleic acid with the sequence of
nucleic acid taken from a bacteriophage particle displaying a
20 said selected peptide.

14. A method according to any of claims 7 to 13 wherein a
peptide with the amino acid sequence of a said selected
peptide is provided in isolated form.

15. A method according to any of claims 7 to 13 wherein a plurality of peptides each with the amino acid sequence of a said selected peptide is provided in isolated form.

16. A method according to any of claims 7 to 13 wherein a mixture of said plurality of peptides is provided in isolated form.

17. A method according to any of claims 14 to 16 wherein said peptide with the amino acid sequence of a said selected peptide, said plurality of peptides or said mixture of plurality of peptides in isolated form is provided by expression from encoding nucleic acid.

18. A method according to any of claims 14 to 16 wherein said peptide with the amino acid sequence of a said selected peptide, said plurality of peptides or said mixture of plurality of peptides in isolated form is provided by peptide synthesis.

19. A method according to any of claims 14 to 18 wherein said peptide with the amino acid sequence of a said selected peptide, said plurality of peptides or said mixture of plurality of peptides in isolated form is formulated into a composition including at least one additional component.

20. A method according to claim 19 wherein said composition includes a pharmaceutically acceptable excipient.

21. A method according to claim 19 wherein said composition
5 includes an adjuvant.

22. A method according to any of claims 7 to 17 wherein the amino acid sequence of a said selected peptide is provided in a fusion with additional amino acids.

23. A method according to claim 22 wherein said fusion includes HCV E2/NS1 protein with said amino acid sequence in the HVR1 position.

24. A method according to claim 22 or claim 23 wherein said
15 fusion is formulated into a composition including at least one additional component.

25. A method according to claim 24 wherein said composition
20 includes a pharmaceutically acceptable excipient.

26. A method according to claim 24 wherein said composition includes an adjuvant.

25 27. A method according to claim 23 wherein said fusion is

included in a recombinant HCV.

28. A method according to claim 27 wherein said recombinant HCV
is formulated into a composition including at least one
5 additional component.

29. A method according to claim 28 wherein said composition
includes a pharmaceutically acceptable excipient.

10 30. A method according to claim 28 wherein said composition
includes an adjuvant.

31. A method according to any of claims 7 to 30 wherein said
selected peptide has or selected peptides each have an amino
15 acid sequence according to the following formula ("Formula
II"):

Q T H T V G G Q A S H Q A S S L T S L F S P G A K Q N

T R G L S

20 R Q P

32. A mixture of 108 different peptides obtainable from a
library according to any of claims 1 to 6, wherein each of the
108 different peptides has an amino acid sequence according to
25 the following formula ("Formula II"):

Q T H T V G G Q A S H Q A S S L T S L F S P G A K Q N

T

R

G

L

S

R

Q

P

5 33. A composition including a plurality of peptides of
Formula II obtainable from a mixture according to claim 32.

34. A composition according to claim 33 including 2 to about
10 different peptides obtainable from said mixture.

10

35. A composition according to claim 33 or claim 34 including
any one or more of the peptides G31, F78, R9, D6, M122 and H1
of which the amino acid sequences are shown in Figure 7(A).

15

36. A composition according to claim 35 including said
peptides R9, F78, H1 and D6 ("MIX1").

37. A composition according to claim 35 including said
peptides M122 and G31 ("MIX2").

20

38. A composition according to claim 35 including said
peptides G31, F78, R9, D6, M122 and H1 ("MIX3").

39. A composition according to any of claims 33 to 38 wherein
25 one or more of said peptides is in a fusion with additional

amino acids.

40. A composition according to claim 39 wherein said fusion
includes HCV E2/NS1 protein with the peptide in the HVR1
5 position.

41. A composition according to claim 40 wherein said fusion
is included in a recombinant HCV.

42. A composition according to any of claims 33 to 41
including at least one additional component.

43. A composition according to claim 42 wherein said
composition includes a pharmaceutically acceptable excipient.

44. A composition according to claim 42 wherein said
composition includes an adjuvant.

45. A peptide of Formula II obtainable from a mixture
20 according to claim 32.

46. A peptide obtainable from a library according to any one
of claims 1 to 5.

47. A peptide according to claim 46 with an amino acid

sequence selected from the group consisting of:

2.11	QHTTVGGVQGRQAHSLTSLFSPGASQN
D6	QTTTTGGQVSHATHGLTGLFSLGPQQK
5 D18	QHTTTGGSASHQASGLTRLFSQGPSQN
F63	QTHVVGQQGRQVSSLVSLFSPGASQK
G31	TTHTVGGSVARQVHSLTGLFSPGPQQK
L13	QHTTVGGSQAHAHSLTRLFSPGSSQN
M69	QTTVVGGSQARAAGLVLVSLFSLGSKQN
10 Z61	QTHVVGQVQGRQTSGLVGLFSPGSKQN
R9	QTTVVGGSQSHTVRGLTSLFSPGASQN
B26	TTTTTGGQAGHQAHSLSLFSFGASQK
B22	QTHVVGQVQSHQTSGLTSLFSPGASQK
B35	QHTTTGGVQGHQTSRLTSLFSPGPSQN
15 D29	TTTVVGQAQAHQTHSLTSLFSPGAKQN
D33	TTTTTGGQQSHTVHGLVGLFSPGSKQN
E26	QHTTVGGVQAHTVRGLTSLFSPGSSQN
F80	QHTTTGGQAGHTASSLTGLFSPGAKQN
F19	QTTTVGGVASHQAHSLSLFSFGAKQK
20 F78	QHTTTGGQAGHQAHSLSLFSFGAKQN
H1	QHTTTGGVVGHATSGLTSLFSPGPSQK
L76	TTTTTVGGQASHQTSLSLTGLFSPGSKQN
B24	TTTTTVGGQASHTTSSLTGLFSPGASQK
M63	QHTTTGGVVSHQTRSLVGLFSPGPQQN
25 M27	QTTTTGGVASHAAHRLTSLFSPGPQQK

M122 QTTTIGGSASHAVSSLTGLFSPGSKQN
M129 QTTVVGGSAGHTASSLVGLFSPGSKQN
M119 TTTTVGGQASHTTSSLTGLFSPGSSQN
R5 QHTTGGQASHQVSSLVSLFSPGAKQK
5 R6 TTTTGGQVGHQTSGLTGLFSPGAQQN
R27 TTHVVGGSASHAVRGLTSLFSPGSSQN

48. A peptide of any of the following amino acid sequences:

10 B14 QTTVTGQASHTTSSLTGLFSPGASQK
B33 ATHATGGQAAHSTHSLTSLFSPGASQK
F81 QTHVTGGSAAHQTGGLTGLFSPGPKQN
B18 QTTVVGGQASHVSRRLTGLFSPGSSQK
E19 TTHTGGQQAHTTSRLVSLFSPGASQK
15 L72 QTTTAAHTTSGLTGLFSPGAKQN
D20 QTHVTGVAGRQTSGLVSLFSPGSSQN
D30 QGGVQGHTTSSLVGLFSPGSSQN

49. A composition including a peptide according to any of
20 claims 46 to 48.

50. A composition including a plurality of peptides
according to any of claims 46 to 48.

25 51. A composition according to claim 50 including 2 to about

10 different peptides according to any of claims 46 to 48.

52. A composition according to any of claims 49 to 51 wherein one or more of said peptides is in a fusion with additional
5 amino acids.

53. A composition according to claim 52 wherein said fusion includes HCV E2/NS1 protein with the peptide in the HVR1
position.

54. A composition according to claim 53 wherein said fusion is included in a recombinant HCV.

55. A composition according to any of claims 49 to 54
15 including at least one additional component.

56. A composition according to claim 55 wherein said composition includes a pharmaceutically acceptable excipient.

20 57. A composition according to claim 55 wherein said composition includes an adjuvant.

58. Nucleic acid encoding a peptide according to any of claims 45 to 48.

59. Nucleic acid encoding a plurality of peptides according to any of claims 45 to 48.

60. Nucleic acid according to claim 58 or claim 59 operably linked to regulatory sequences for expression of the encoded peptide or peptides.

61. A host cell containing nucleic acid according to claim 60.

62. A method for production of a peptide or peptides according to any of claims 45 to 48, the method including causing expression from nucleic acid according to claim 60.

63. A method for production of a peptide or peptides according to any of claims 45 to 48, the method including culturing host cells according to claim 61 under conditions for production of said peptide or peptides.

64. A method according to claim 62 or claim 63 including isolation and/or purification of said peptide or peptides.

65. A method according to any of claims 62 to 64 including formulating said peptide or peptides into a composition including at least one additional component.

66. A method according to claim 65 wherein said composition includes a pharmaceutically acceptable excipient.

67. A method according to claim 65 wherein said composition
5 includes an adjuvant.

68. A method of obtaining one or more antibody molecules containing a binding site able to bind an epitope in the HVR1 of a plurality of HCV strains, the method including bringing
10 into contact a population of antibody molecules and a peptide according to any of claims 45 to 48, and selecting one or more antibody molecules of the population able to bind said peptide.

69. A method according to claim 68 including bringing the
15 population of antibodies into contact with a plurality of peptides according to any of claims 45 to 48.

70. A method according to claim 68 or claim 69 wherein the
20 peptides are provided in a fusion with additional amino acids.

71. A method according to any of claims 68 to 70 wherein said
peptide or plurality of peptides is administered to a non-
25 human mammal to bring it or them into contact with a

population of antibody molecules produced by the mammal's immune system, then one or more antibody molecules able to bind said peptide or peptides is taken from the mammal.

5 72. A method according to any of claims 68 to 70 wherein the peptide or peptides are administered to a non-human mammal to bring them into contact with a population of antibody molecules produced by the mammal's immune system, then cells producing antibody molecules able to bind the peptide or
10 peptides are taken from the mammal.

73. A method according to claim 72 wherein antibody molecules are taken from said cells or descendants thereof.

15 74. A method according to any of claims 71 to 73 wherein the mammal is sacrificed.

75. A method according to any of claims 68 to 70 wherein the population of antibody molecules is displayed on the surface
20 of bacteriophage particles, each particle containing nucleic acid encoding the antibody molecule displayed on its surface.

76. A method according to claim 75 wherein nucleic acid is taken from a bacteriophage particle displaying an antibody
25 molecule able to bind said peptide or peptides.

77. A method according to claim 76 including producing an antibody molecule by expression from nucleic acid with the sequence of nucleic acid taken from a bacteriophage particle displaying an antibody molecule able to bind said peptide or peptides.

78. A method according to any of claims 68 to 77 wherein an antibody molecule able to bind said peptide or peptides is provided in isolated form.

79. A method according to claim 78 wherein a plurality of antibody molecules able to bind said peptide or peptides are provided in isolated form.

80. A method according to claim 79 wherein a mixture of said plurality of antibody molecules is provided in isolated form.

81. A method according to any of claims 78 to 80 wherein said antibody molecule, plurality of antibody molecules or mixture of plurality of antibody molecules in isolated form is provided by expression from encoding nucleic acid.

82. A method according to any of claims 78 to 81 wherein said antibody molecule, plurality of antibody molecules or mixture of plurality of antibody molecules in isolated form is

formulated into a composition including at least one additional component.

83. A method according to claim 82 wherein said composition includes a pharmaceutically acceptable excipient.

84. An antibody molecule obtained by a method according to any of claims 68 to 83.

85. Use of a composition according to any of claims 33 to 44 in the manufacture of a medicament for raising in a mammal antibodies able to bind HCV HVR1 epitopes.

86. Use of a peptide according to any of claims 45 to 48 in the manufacture of a medicament for raising in a mammal antibodies able to bind HCV HVR1 epitopes.

87. Use of a composition according to any of claims 49 to 57 in the manufacture of a medicament for raising in a mammal antibodies able to bind HCV HVR1 epitopes.

88. Use of nucleic acid according to any of claims 58 to 60 in the manufacture of a medicament for raising in a mammal antibodies able to bind HCV HVR1 epitopes.

89. Use of an antibody molecule according to claim 84 in the manufacture of a medicament for increasing in a mammal the level of antibodies able to bind HCV HVR1 epitopes.

90. A method of raising in a mammal antibodies able to bind HCV HVR1 epitopes, the method including administering a composition according to any of claims 33 to 44 to the mammal.

91. A method of raising in a mammal antibodies able to bind HCV HVR1 epitopes, the method including administering a peptide according to any of claims 45 to 48 to the mammal.

92. A method of raising in a mammal antibodies able to bind HCV HVR1 epitopes, the method including administering a composition according to any of claims 49 to 57 to the mammal.

93. A method of raising in a mammal antibodies able to bind HCV HVR1 epitopes, the method including administering nucleic acid according to any of claims 58 to 60 to the mammal.


94. A method of increasing in a mammal the level of antibodies able to bind HCV HVR1 epitopes, the method including administering an antibody according claim 84 to the mammal.

95. A method according to any of claims 90 to 94 which is prophylactic.

96. A method according to any of claims 90 to 94 wherein the
5 mammal has an HCV infection.

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

A



B




Fig. 1




Fig. 2




Fig. 3

A

	R9	H1	M63	M122
C7	0.14	0.13	0.00	0.22
C8	1.67	1.83	1.05	0.38
C9	2.30	0.65	0.21	0.11
C10	1.23	1.30	0.71	0.64
C12	0.16	1.20	0.20	1.09
C13	0.90	2.06	0.57	0.19
C14	0.47	0.63	1.09	2.27
C17	1.48	1.35	1.00	0.00
C23	0.00	0.88	2.65	0.00
C27	0.00	0.00	0.00	3.17
C28	2.98	0.15	0.00	1.98
C29	0.00	0.00	2.83	1.17
C30	0.18	0.00	2.85	1.17
C40	3.17	1.84	0.20	2.96
C48	3.07	2.88	0.00	2.56
C49	0.12	0.00	0.00	0.00
C50	0.00	0.00	0.12	0.00
C56	0.33	0.12	0.00	0.00
C58	2.85	1.42	0.38	0.35
C62	0.00	0.00	0.13	0.00

frequency 75% 70% 70% 70% 100%

B

	R9	H1	M63	M122
1V	0.49	2.31	0.00	0.20
2V	0.00	0.19	0.11	0.00
3V	0.65	1.60	1.73	0.62
4V	0.25	0.00	0.00	0.29
5V	1.75	2.47	0.31	0.00
7V	0.60	1.09	1.16	0.88
8V	0.30	0.88	0.00	0.00
9V	0.00	0.59	0.00	0.00
10V	0.58	0.11	1.98	0.00
1P	0.00	0.00	0.00	0.33
5P	0.24	0.28	0.44	0.00
6P	0.47	1.52	0.27	0.31
7P	0.78	1.33	1.00	0.00
8P	0.68	0.37	0.14	0.38
10P	1.20	1.12	0.81	0.88
11P	0.32	0.44	0.00	0.22
12P	1.50	1.08	0.84	0.90
13P	0.49	0.00	0.00	0.31

frequency 83% 83% 61% 61% 100%

C

	R9	H1	M63	M122
X1	0.00	0.00	0.00	0.00
X2	1.37	0.17	0.21	0.88
X3	0.15	0.56	0.38	0.00
X4	0.00	0.00	0.00	0.00
X5	0.00	0.14	0.00	0.00
X6	0.25	0.00	0.00	0.31
X7	0.66	0.83	0.60	0.34
X8	1.04	1.31	0.98	0.45
X9	0.96	0.21	0.00	0.00
X10	0.00	0.00	0.00	0.00
X11	0.74	0.33	0.11	0.91
X12	0.00	0.00	0.00	0.00
X13	2.30	0.18	0.54	0.00
X14	1.20	0.00	0.00	0.00
X15	2.38	0.00	0.00	1.60
X16	1.92	2.30	1.86	2.19
X17	0.00	0.00	0.00	0.00
X18	0.00	0.00	0.00	0.00
X19	0.00	0.00	0.00	0.00
X20	0.47	0.33	0.26	0.00
X21	0.00	0.86	1.45	1.96
X22	0.37	0.44	0.44	0.12
X23	0.61	0.60	0.10	0.00
X24	0.00	0.00	0.80	0.73
X25	0.00	0.00	0.00	0.47
X26	0.00	0.00	0.00	0.00
X27	0.00	0.00	0.00	0.00
1NV	0.00	1.50	0.22	0.00
2NV	0.00	0.40	0.23	0.00
3NV	0.10	0.11	0.00	0.00
4NV	0.00	0.00	0.00	0.00
5NV	0.00	0.00	0.00	0.00
6NV	0.00	0.00	0.00	0.00
11NV	0.10	0.00	0.00	0.53
12NV	0.00	0.00	0.41	0.00
13NV	0.00	0.00	0.00	0.00
15NV	0.12	0.00	0.00	0.19
16NV	0.52	0.84	0.36	0.60
17NV	0.64	0.52	0.41	1.14
3P	0.00	0.00	0.00	0.00
4P	0.00	0.00	0.00	0.00

frequency 46% 44% 41% 37% 63%

Fig. 4




Fig. 5




Fig. 6

A

mimotope	sequence
N5	TTTTTGGVQGHTTRGLVRLFSLGSKQN
R6	TTTTTGGQVGHQTSGLTGLFSPGAQQN
D6	TTTTTGGQVSHATHGLTGLFSLGPQOK
R9	QTTVVGGSQSHTVRGLTSLFSPGASQN
H1	QTHTTGGVVGHATSGLTSLFSPGPSQK
G31	TTHTVGGSVARQVHSLTGLFSPGPQOK
M122	QTTTTGGSASHAVSSLTGLFSPGSKQN
B14	QTTVTG-QASHTTSSLTGLFSPGASQK
F78	QTHTTGGQAGHQAHS�TGLFSPGAKQN

B





Fig. 7

A

mimotope G31 F78 R9 D6 M122 H1 N5

titre (x100) 330 1000 330 130 10 33 5



cross-reactivity 77% 70% 60% 60% 44% 42% 28% **total: 91%**

B

MIX3 MIX1 MIX2

45 25 30



95% 84% 84%

Fig. 8

B14 QTTVT.GQASHTTSSLTGLFSPGASQK
 B24 TTTTVGGQASHTTSSLTGLFSPGASQK
 D6 QTTTTGGQVSEATHGLTGLFSLGPQQK
 E19 TTET.GGQQAHTTSLVSLFSPGASQK
 F78 QTHTTGGQAGHQHSLTGLFSPGAKQN
 G31 THTTVGGSVARQVHSLTGLFSPGPQQK
 H1 QTHTTGGVVGHATSLTSLFSPGFSQK
 M63 QTHTTGGVVSEHTSLVGLFSPGPQQN
 M122 QTTTTGGSASEAVSSLTGLFSPGSKQN
 R6 TTTTTGGQVGHQTSLTGLFSPGAQQN
 R9 QTTVVGGSQSHTVRGLTSLFSPGASQN





Fig. 9

DECLARATION, POWER OF ATTORNEY AND POWER TO INSPECT

As a below named inventor, I hereby declare:

that my residence, post office address and citizenship are as stated below next to my name;

that I verify below I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the invention entitled: **MIMOTOPE OF HYPERVARIABLE REGION 1 OF THE E2 GLYCOPROTEIN OF HCV AND USES THEREOF**

the specification of which (check one(s) applicable)

☒ was filed 14 May 1999 as International Application No. PCT/EP99/03344

☐ was filed 18 January 2000 and U.S. Application No. 09/463,098

☐ and was amended by Amendment filed _____ (if applicable); [or];

☐ is attached to this Declaration, Power of Attorney and Power to Inspect;

that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above; and

that I acknowledge my duty to disclose information which is material to the examination of this application in accordance with Rule 56(a) (37 CFR §1.55(a)).

CLAIM UNDER 35 USC §119: I hereby claim foreign priority benefits under 35 USC §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)

Application No.
PCT/EP99/03344
9610756.B

Country
EP
EP

Filing Date
Day-Mo-Year
14 May 1999
19 May 1999

2- POWER OF ATTORNEY: As inventor, I hereby appoint **DANN, DORFMAN, HERRELL AND SKILLMAN, P.C.**, of Philadelphia, PA, and the following individual(s) as my attorney or attorneys with full power of substitution to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: **Kathleen D. Rigaut, Ph.D., J.D. Reg. No. 43,407** and **Patrick J. Hagan, Reg. No. 27,643**

POWER TO INSPECT: I hereby give **DANN, DORFMAN, HERRELL AND SKILLMAN, P.C.** of Philadelphia, PA or its duly accredited representatives power to inspect and obtain copies of the papers on file relating to this application.

SEND CORRESPONDENCE TO: CUSTOMER NUMBER 000110.

DIRECT INQUIRIES TO: Telephone: (215) 563-4100
Facsimile: (215) 563-4044

I hereby declare that all statements made here in of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

SOLE OR FIRST JOINT INVENTOR

Full Name Alfredo Nigroia-
First Middle Last

Signature Alfredo Nigroia

Date May 4, 2000

Residence ROME ITALY
City State or Country

Citizenship ITALIAN

Post Office Address:

Via T. Vivanti, No. 108

ROME ITALY 00144
City State or Country Zip Code

SECOND JOINT INVENTOR (IF ANY)

Full Name Armin Lehn
First Middle Last

Signature Armin Lehn

Date May 4, 2000

Residence ROME ITALY
City State or Country

Citizenship GERMAN

Post Office Address:

B. G. MARIA LIBERATRICE 18

ROME ITALY 00153
City State or Country Zip Code

THIRD JOINT INVENTOR (IF ANY)

3- Full Name Anna Tramontano
First Middle Last

Signature Anna Tramontano

Date MAY FOURTH, 2000

Residence Rome Italy ITV
City State or Country

Citizenship ITALIAN

Post Office Address:

Via E. Mattei, 19

Rome Italy 00045
City State or Country Zip Code

FOURTH JOINT INVENTOR (IF ANY)

4- Full Name Riccardo Cozzani
First Middle Last

Signature Riccardo Cozzani

Date MAY EIGHTH, 2000

Residence Rome Italy ITV
City State or Country

Citizenship ITALIAN

Post Office Address:

Via M. Massimo, 16

Rome Italy 00144
City State or Country Zip Code